CVA TBI

Study Notes

SECTION 1: STROKE AND PSYCHIATRY

1.1 Epidemiology of Neuropsychiatric Complications Post-Stroke

Stroke is one of the leading causes of acquired disability worldwide. Beyond motor and sensory deficits, neuropsychiatric complications are pervasive and often under-recognized. Up to 70–80% of stroke survivors will develop at least one neuropsychiatric syndrome within the first year. These syndromes contribute independently to functional disability, caregiver burden, and mortality.

Key prevalence figures (exam-relevant):

• Post-stroke depression (PSD): 30–50% (lifetime); 25–35% in acute phase
• Post-stroke anxiety: 20–25%
• Post-stroke psychosis: ~5% (hallucinations, delusions)
• Post-stroke mania: rare, ~1–2%; more common with right hemisphere lesions
• Vascular cognitive impairment (VCI): 20–30% at 3 months; up to 50% at 5 years
• Post-stroke apathy: 20–40% (often overlapping with depression)
• Emotional incontinence / pseudobulbar affect: 15–20%
• Anosognosia: 10–30% (especially with right hemisphere infarcts)

1.2 Post-Stroke Depression (PSD)

Definition and Diagnostic Challenge

PSD refers to a major or minor depressive episode occurring in the context of stroke. DSM-5 classifies it under "Depressive Disorder Due to Another Medical Condition (Stroke)", not as a primary MDD. This distinction has treatment implications: somatic symptoms of stroke (fatigue, sleep disturbance, psychomotor slowing) overlap heavily with depressive criteria, making purely symptom-based diagnosis unreliable. Emphasis should be placed on cognitive-affective symptoms: anhedonia, hopelessness, worthlessness, suicidal ideation.

Robinson's Left Frontal Hypothesis (CRITICAL FOR EXAM)

Robert Robinson and colleagues at Johns Hopkins (1980s–1990s) proposed the neuroanatomical model for PSD. The central thesis:

The proposed mechanism:

• Left DLPFC → projects to limbic structures via the fronto-striato-thalamic-cortical circuit
• Stroke disrupts descending serotonergic and noradrenergic projections from the frontal cortex to the limbic system
• The left hemisphere, being dominant for approach-related positive affect regulation, when damaged, leads to unopposed negative affect from the right
• Proximity of lesion to the frontal pole (anterior pole) correlates with severity of depression in the left hemisphere

Evidence supporting Robinson:

• Early studies (1984, 1987) showed left frontal lesions had Hamilton Depression scores 2–3x higher than right frontal lesions
• The inverse was true for mania, right hemisphere lesions correlated more strongly with manic episodes
• Lesion-to-frontal-pole distance (on CT/MRI) was inversely correlated with depression severity for left hemisphere strokes

Critiques of Robinson's hypothesis:

• Later meta-analyses (Carson et al., 2000; Bhogal et al., 2004) found the left-frontal relationship was most robust in hospital-based samples (selection bias)
• Community-based studies showed weaker or absent lateralization
• The relationship may be strongest in the first 1–3 months post-stroke
• Methodological heterogeneity: different rating scales, imaging modalities, time points

Current consensus: Robinson's hypothesis is historically important and continues to be cited in exams. The left-frontal relationship is real but not absolute, PSD is multifactorial (neuroanatomical, psychosocial, premorbid vulnerability).

Prevalence Details

Note: PSD can develop at any time post-stroke. Late-onset PSD (>6 months) may be more related to psychosocial adjustment and disability burden.

Risk Factors for PSD

Neurological:

• Lesion location: left frontal, left basal ganglia
• Lesion volume (larger = higher risk)
• Cortical vs subcortical: cortical involvement increases risk
• Ischemic > hemorrhagic (though both occur)

Psychosocial:

• Pre-stroke depression or anxiety (strongest predictor)
• Poor social support
• Female sex
• Cognitive impairment
• Functional disability (ADL dependence)
• Living alone

Clinical Presentation

PSD may present with atypical features compared to primary MDD:

• More prominent apathy (overlapping syndrome)
• Emotional lability (crying spells without full sadness)
• Greater neurovegetative symptoms
• Higher rates of executive dysfunction complicating insight
• Variable suicidal ideation (present, but less common than primary MDD)

Differentiate PSD from adjustment disorder: PSD has biological substrate; both may be clinically similar acutely.

Assessment Tools for PSD

1. Hamilton Rating Scale for Depression (HDRS), gold standard; limitations with somatic items
2. Montgomery-Asberg Depression Rating Scale (MADRS), less confounded by somatic symptoms; preferred in stroke
3. Patient Health Questionnaire-9 (PHQ-9), validated in stroke; practical for screening
4. Geriatric Depression Scale (GDS), useful in elderly stroke survivors
5. Visual Analogue Scale for Depression, for aphasic patients

Treatment of PSD

Pharmacological:

Swipe to compare →

Duration: Treat for minimum 6–12 months after response. Relapse common if stopped early.

Non-pharmacological:

• Cognitive Behavioral Therapy (CBT), modified for aphasia/cognitive deficits
• Problem-solving therapy
• Motivational interviewing
• Exercise, RCT evidence for post-stroke depression reduction
• Social support interventions
• Caregiver psychoeducation

Prevention: Sertraline and escitalopram have been trialed as prophylactic agents; evidence is mixed but promising for high-risk patients (left frontal lesion, pre-stroke depression).

1.3 Post-Stroke Anxiety

• Prevalence: 20–25% at 3 months; often co-occurs with depression (50% comorbidity)
• More common with right hemisphere lesions (some data) and cortical lesions
• Generalized Anxiety Disorder pattern most common; PTSD also possible
• Assessment: Hamilton Anxiety Scale, GAD-7
• Treatment: SSRIs (first line), buspirone, CBT
• Benzodiazepines: caution in stroke (fall risk, cognitive effects, respiratory depression with brainstem strokes)

1.4 Post-Stroke Psychosis

• Rare: 3–5% of stroke survivors
• More common with right hemisphere lesions, especially temporal-parietal-occipital regions
• Also associated with subcortical lesions (thalamus, caudate)
• Hallucinations: usually visual > auditory; peduncular hallucinosis (vivid visual hallucinations after brainstem/thalamic strokes) is a classic presentation
• Delusions: persecutory, referential; capgras syndrome reported with bilateral lesions
• Often brief and resolves; organic basis means lower antipsychotic doses may suffice
• Assess for delirium (first exclude)
• Management: low-dose risperidone or quetiapine; avoid typical antipsychotics if possible (extrapyramidal risk, especially with basal ganglia lesions)

1.5 Post-Stroke Mania

• Rare (~1–2%); associated with right hemisphere lesions
• Neuroanatomy: right basal temporal region, orbitofrontal cortex, right caudate, thalamus
• Mechanism: release of left-hemisphere from right-hemisphere tonic inhibition; or disruption of limbic regulatory circuits
• Features: euphoria, decreased need for sleep, grandiosity, pressured speech, impulsive behavior
• May occur weeks to months after stroke
• Secondary mania criteria (Starkstein & Robinson): euphoric mood + 2 of: increased activity, grandiosity, decreased sleep, increased speech, distractibility, reckless behavior
• Treatment: mood stabilizers (valproate preferred in neurological setting), atypical antipsychotics; lithium less favored due to narrow TI and renal concerns in elderly

1.6 Post-Stroke Apathy

Definition: Apathy is a motivational syndrome, diminished goal-directed behavior, reduced emotional reactivity, and decreased cognitive engagement, occurring in the absence of significant subjective distress (distinguishing it from depression).

Prevalence: 20–40% post-stroke; often persists longer than depression

Neuroanatomy:

• Anterior cingulate cortex (ACC), critical hub for motivation generation
• Basal ganglia (striatum, especially caudate)
• Frontal white matter tracts
• Infarcts in these areas directly cause apathy

Assessment:

• Apathy Evaluation Scale (AES), most validated
• Neuropsychiatric Inventory (NPI), apathy subscale
• Starkstein Apathy Scale

Distinguishing Apathy from Depression:

Treatment:

• No proven pharmacological treatment (as of 2026)
• Methylphenidate and rivastigmine have some evidence
• Dopamine agonists (bromocriptine), small studies
• Behavioral activation, structured routines, caregiver coaching
• Management of co-occurring depression improves apathy secondarily

1.7 Emotional Incontinence / Pseudobulbar Affect (PBA)

Definition: Pseudobulbar affect is pathological emotional expression, involuntary, uncontrollable episodes of laughing or crying (or both) that are often incongruent with the patient's subjective emotional state.

Mechanism:

• Loss of voluntary cortical inhibition of brainstem (pontine) motor-emotional circuits
• Specifically: damage to corticobulbar pathways disrupts inhibitory descending signals to the brainstem's emotional integration center
• Serotonin and glutamate dysregulation implicated

Associated conditions: Stroke (most common), TBI, ALS, MS, Parkinson's disease, dementias

Clinical features:

• Episodes typically brief (seconds to minutes), then full recovery
• Patient often embarrassed and aware the reaction is excessive
• Distinguish from ictal laughter (gelastic seizures), usually more prolonged, associated with other ictal features
• Distinguish from labile mood in bipolar disorder, no loss of control in bipolar

Assessment: CNS-LS (Center for Neurologic Study, Lability Scale)

Treatment:

• Dextromethorphan/Quinidine (Nuedexta), FDA-approved (2010); the standard pharmacological treatment; quinidine inhibits CYP2D6 metabolism of dextromethorphan (which is the active agent); mechanism: sigma-1 receptor modulation + NMDA antagonism
• SSRIs (fluoxetine, sertraline), often first used clinically; good evidence
• Amitriptyline, older evidence; effective
• Behavioral strategies: distraction, controlling breathing

1.8 Anosognosia

Definition: Failure of a patient to recognize or acknowledge their own neurological deficit (e.g., hemiplegia, hemianopia, aphasia).

Prevalence: 10–30% post-stroke; most common with right hemisphere strokes → left-sided neglect + anosognosia for left hemiplegia

Neuroanatomy:

• Right parietal cortex (especially right supramarginal gyrus, inferior parietal lobule)
• Thalamus, basal ganglia connections
• Frontal lobe involvement for metacognitive awareness

Mechanism: Disruption of body schema and multimodal integration; the right parietal lobe is dominant for body awareness and spatial attention

Clinical significance:

• Interferes with rehabilitation participation (patient denies deficits, refuses therapy)
• Creates caregiver conflict
• Prognosis: may resolve as stroke recovery progresses; persistent anosognosia = poor functional outcome

Related syndromes:

• Anosodiaphoria: acknowledges deficit but shows inappropriate indifference
• Anton's syndrome: cortical blindness with denial of visual loss (occipital lesion)
• Neglect (hemispatial): inattention to contralateral space (not the same as anosognosia, but often co-occurs)

1.9 Vascular Cognitive Impairment (VCI)

Spectrum:

1. Vascular Mild Cognitive Impairment (VaMCI): Cognitive decline in ≥1 domain, not affecting daily function significantly, attributed to vascular disease
2. Vascular Dementia (VaD): Cognitive decline sufficient to impair daily function, attributed to cerebrovascular disease
3. Mixed Dementia: VaD + Alzheimer's pathology (most common form in clinical practice)

Subtypes of VaD:

• Multi-infarct dementia: multiple large cortical infarcts; stepwise decline
• Strategic infarct dementia: single infarct in critical location (thalamus, basal forebrain, angular gyrus); profound but focal deficits
• Small vessel disease / Subcortical ischemic VaD: leukoaraiosis, lacunar infarcts; prominent executive dysfunction, gait disturbance, urinary symptoms; Binswanger's disease is an extreme form
• CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, NOTCH3 mutation; genetic subcortical VaD; migraine with aura, recurrent strokes, psychiatric symptoms

Clinical profile of VaD (vs Alzheimer's):

• Abrupt onset, stepwise progression (vs gradual in AD)
• Executive dysfunction > memory (vs memory-first in AD)
• Gait disturbance early (vs late in AD)
• Focal neurological signs (vs absent in early AD)
• Preserved recall with cuing (vs impaired in AD)
• Psychiatric symptoms: depression, apathy, emotional lability more common in VaD

Neuroimaging:

• MRI: white matter hyperintensities (WMH), lacunes, cortical infarcts, atrophy
• Fazekas scale: quantifies periventricular and deep WMH (0–3)
• NINDS-AIREN criteria (research): cerebrovascular disease + cognitive decline + temporal relationship between stroke and cognitive change

Management of VaD:

• Vascular risk factor control (primary intervention)
• Antiplatelet therapy (aspirin, clopidogrel)
• Statins, antihypertensives
• Cholinesterase inhibitors (donepezil, rivastigmine): modest benefit for VaD (similar to AD); evidence from RCTs
• Memantine: some evidence
• Psychiatric comorbidities treated as above

SECTION 2: NEUROANATOMICAL CORRELATES OF PSYCHIATRIC SYNDROMES

2.1 Frontal Lobe Syndromes

The frontal lobe comprises ~30% of cortical surface. Three main functional subdivisions produce distinct psychiatric syndromes when damaged.

2.1.1 Dorsolateral Prefrontal Cortex (DLPFC) Syndrome

Anatomy: Broadmann areas 9, 10, 45, 46; projects to caudate nucleus

Functions: Working memory, executive function, planning, set-shifting, abstract reasoning, verbal fluency

Lesion syndrome (Dysexecutive Syndrome):

• Impaired planning and organization (Tower of London test failure)
• Poor set-shifting (WCST, Wisconsin Card Sorting Test failure)
• Reduced verbal fluency (FAS test impaired)
• Working memory deficits
• Difficulty with abstract reasoning
• Pseudodepression: flat affect, apathy, reduced motivation; resembles depression but without dysphoric mood

Associated conditions: ADHD (under-activation), Schizophrenia (hypofrontality), Frontotemporal Dementia, DLPFC strokes, Parkinson's disease

2.1.2 Orbitofrontal Cortex (OFC) Syndrome

Anatomy: Broadmann areas 11, 12, 13, 14; projects to amygdala, nucleus accumbens, mediodorsal thalamus

Functions: Reward processing, social cognition, impulse inhibition, emotional regulation, decision-making with social cues

Lesion syndrome (Pseudopsychopathic Syndrome / Orbito-frontal Syndrome):

• Disinhibition, socially inappropriate behavior, sexual remarks, reckless behavior
• Impulsivity, poor response inhibition (Go-No-Go test failure)
• Poor decision-making in social contexts (Somatic Marker Hypothesis, Damasio: inability to use emotional signals to guide decisions → "Iowa Gambling Task" failure)
• Grandiosity, euphoria (can mimic mania)
• Hypersexuality
• Labile affect
• Reduced concern for social consequences
• Classic case: Phineas Gage (1848), traumatic damage to orbitofrontal and ventromedial PFC; personality change from responsible to impulsive, irresponsible

Associated conditions: Bipolar disorder (OFC dysfunction), antisocial personality, addiction (OFC governs reward valuation), TBI affecting frontal poles

2.1.3 Medial Prefrontal / Anterior Cingulate Cortex (ACC) Syndrome

Anatomy: Broadmann area 24 (anterior cingulate), medial surfaces; projects to supplementary motor area, limbic structures

Functions: Motivated behavior, error monitoring, conflict detection, attention allocation, initiation

Lesion syndrome (Akinetic Mutism / Motivational Deficits):

• Akinetic mutism (severe): patient is awake, eyes open, tracks objects, but does not speak, move, or respond, extreme form of amotivation
• Apathy (moderate): loss of spontaneous behavior, reduced emotional expression
• Abulia: intermediate state between akinetic mutism and apathy
• Reduced initiation without explicit prompting
• Preserved cognition when prompted vs DLPFC syndrome

Associated conditions: Anterior cerebral artery stroke (bilateral ACA infarct → classic akinetic mutism), deep frontal meningiomas, bipolar depression (ACC hyperactivity in some models), OCD (ACC hyper-activation)

2.1.4 Frontal Lobe Tests (Bedside)

Frontal Assessment Battery (FAB), 6 components:

1. Similarities (conceptualization)
2. Lexical fluency (mental flexibility)
3. Luria motor series (programming)
4. Conflicting instructions (sensitivity to interference)
5. Go-No-Go (inhibitory control)
6. Prehension behavior (environmental autonomy)

Score ≤12/18 suggests frontal dysfunction.

2.2 Parietal Lobe Syndromes

Dominant (Left) Parietal Lesions

Gerstmann Syndrome (angular gyrus, BA39):

• Finger agnosia
• Left-right disorientation
• Agraphia
• Acalculia

(Mnemonic: FLAG, Finger agnosia, L-R disorientation, Agraphia, aGraphia → wait, use "Four A's of Gerstmann": Agraphia, Acalculia, Agnosia for fingers, Aleft-right disorientation)

Apraxia: Ideomotor apraxia (cannot mimic gestures), ideational apraxia (cannot sequence complex actions), dominant parietal

Aphasia (Wernicke's): If extending to posterior temporal/superior temporal sulcus

Non-dominant (Right) Parietal Lesions

Hemispatial Neglect: Inattention to left visual/motor space

Anosognosia: As above

Dressing Apraxia: Cannot dress due to spatial orientation failure

Constructional Apraxia: Cannot draw/copy figures (clock test, pentagon copying)

Amorphosynthesis: Simultaneous extinction; unable to perceive two simultaneous stimuli

2.3 Temporal Lobe Syndromes

Dominant (Left) Temporal

• Wernicke's aphasia: fluent but incomprehensible speech; poor comprehension; paraphasias
• Verbal memory impairment (left hippocampus)
• Anomia (temporal tip)

Non-dominant (Right) Temporal

• Non-verbal memory impairment (faces, music, spatial patterns)
• Prosopagnosia (right occipito-temporal)
• Amusia

Bilateral / Medial Temporal

• Korsakoff-like amnesia: bilateral hippocampal damage
• Urbach-Wiethe disease: bilateral amygdala calcification → fearlessness, social behavior changes

Temporal Lobe Epilepsy / Kluver-Bucy Syndrome

Bilateral anterior temporal lobe destruction (amygdala + anterior temporal):

• Hyperorality
• Hypersexuality
• Placidity (loss of fear, rage)
• Visual agnosia
• Hypermetamorphosis (excessive exploration of objects)

Interictal Personality Changes (Geschwind Syndrome) with temporal lobe epilepsy:

• Hypergraphia
• Religiosity
• Hyposexuality
• Viscosity (circumstantial thinking)
• Philosophical preoccupation

2.4 Lesion-Psychiatric Syndrome Summary Table

SECTION 3: TRAUMATIC BRAIN INJURY (TBI) AND NEUROPSYCHIATRY

3.1 Classification of TBI

TBI is classified by severity using the Glasgow Coma Scale (GCS) assessed at 30 minutes post-injury (or at emergency presentation):

GCS Components:

• Eye opening: 1–4
• Verbal response: 1–5
• Motor response: 1–6
• Total: 3–15 (3 = worst; 15 = normal)

Alternative classification markers:

• Post-Traumatic Amnesia (PTA): period of confusion and memory impairment after TBI; Galveston Orientation and Amnesia Test (GOAT) for assessment
• Loss of Consciousness (LOC): duration correlates with severity

Additional severity markers:

• Neuroimaging: CT/MRI findings (hemorrhage, contusion, diffuse axonal injury)
• Biomarkers: S100B, GFAP, neuron-specific enolase, elevated indicate injury; GFAP most specific
• IMPACT score, Prognostic model for severe TBI

3.2 Acute Psychiatric Effects of TBI

Acute Confusional State / Delirium Post-TBI

• Almost universal with moderate-severe TBI; variable with mild
• Mechanism: neuroinflammation, diffuse axonal injury, neurotransmitter dysregulation
• Features: disorientation, agitation, fluctuating consciousness, post-traumatic amnesia
• Management: orientation aids, quiet environment, minimize sedation, low-dose antipsychotics if agitation

Acute Emotional/Behavioral Changes

• Agitation: up to 70% in ICU setting post-severe TBI
• Emotional lability
• Disinhibition
• Anxiety/fear

3.3 Post-Concussion Syndrome (PCS)

Definition: A constellation of symptoms persisting beyond the expected recovery period (>1–3 months) after mild TBI (concussion).

DSM-5: Listed as "Neurocognitive Disorder Due to Traumatic Brain Injury" (mild form)

ICD-10: Post-concussion syndrome (F07.2), explicitly coded

Symptoms Triad:

1. Somatic: headache (most common, tension-type pattern), dizziness, fatigue, sleep disturbance, photophobia, phonophobia, visual disturbance
2. Cognitive: memory problems, poor concentration, slow processing, word-finding difficulty
3. Affective/Behavioral: irritability, anxiety, depression, emotional lability, reduced frustration tolerance

Pathophysiology:

• Neurometabolic cascade (Giza & Hovda): ionic flux, excitotoxicity, mitochondrial dysfunction, creates a period of neuronal vulnerability
• Cerebral blood flow autoregulation disruption
• Neuroinflammation
• Psychological factors (health anxiety, avoidance, litigation)
• The biopsychosocial model applies: biological injury + psychological response + social reinforcement

Prognosis:

• 80–90% of concussions resolve within 7–10 days
• 10–20% develop PCS
• Female sex, pre-existing headaches/anxiety/depression, lower education, prior concussion, negative expectations (nocebo effect) predict prolonged recovery
• Most PCS resolves within 3 months; <5% persist beyond 1 year

Management:

• Cognitive rest (brief, then graduated return to activity, "SCAT5 Return to Play Protocol")
• Treat specific symptoms: headache (amitriptyline, topiramate), sleep (melatonin, trazodone), mood (SSRI)
• CBT for health anxiety component
• Occupational therapy for cognitive rehabilitation
• Avoid prolonged rest, increases symptom perpetuation
• Gradual return to school/work protocol
• Second Impact Syndrome (see 3.7)

3.4 Chronic Traumatic Encephalopathy (CTE)

Definition: A progressive neurodegenerative disease caused by repetitive traumatic brain injury (typically sub-concussive and concussive impacts), characterized by accumulation of hyperphosphorylated tau protein in perivascular regions.

Context: Described in American football players (NFL), boxers (Dementia Pugilistica), military veterans (blast injury)

Neuropathology:

• Tau deposits in neurons, astrocytes, and cell processes in perivascular distribution, perivascular foci at depths of cortical sulci (pathognomonic)
• Diffuse axonal injury
• TDP-43 inclusions in later stages
• CTE is a posthumous diagnosis, requires brain autopsy

Clinical Stages (McKee et al.):

• Stage I: Headache, loss of attention, short-term memory deficits
• Stage II: Depression, explosivity, impulsivity, executive dysfunction
• Stage III: Executive dysfunction, memory loss, visuospatial problems
• Stage IV: Dementia, severe behavioral changes, Parkinsonism, speech/swallow difficulties

Behavioral Profile:

• Depression (60–80% in documented cases)
• Impulse control disorder
• Substance abuse
• Aggression/explosivity
• Suicidality
• Paranoia
• Progressive memory loss

Key distinction from Alzheimer's:

• CTE: tau-predominant, frontal>temporal, younger onset, trauma history
• AD: amyloid + tau, hippocampal-predominant, age-related

Diagnosis:

• Currently no in-vivo biomarker validated for CTE (research ongoing: tau PET, plasma phospho-tau217)
• Brain MRI: cavum septum pellucidum (seen in boxers, "punched out"), cerebral atrophy
• Diagnosis requires autopsy; neuropathological criteria published 2016 (McKee)

3.5 Personality Change Due to TBI (DSM-5: Personality Change Due to Another Medical Condition)

Prevalence: 50–80% of moderate-severe TBI survivors show personality changes

DSM-5 Subtypes:

• Labile type: affective instability
• Disinhibited type: impulse control failure (orbitofrontal damage)
• Aggressive type: aggression/irritability
• Apathetic type: marked indifference (frontal/ACC)
• Paranoid type: suspiciousness
• Combined type
• Other/unspecified

Neuroanatomical basis:

• Frontal lobe damage (most common in TBI, frontal poles vulnerable to coup-contrecoup against bony skull ridges)
• Orbitofrontal: disinhibition, impulsivity
• DLPFC: apathy, executive dysfunction
• Temporal lobes: emotional dysregulation, memory
• Anterior temporal + amygdala: emotional control, aggression threshold

Assessment:

• Frontal Systems Behavior Scale (FrSBe)
• Neuropsychological Behavior and Affect Profile (NBAP)
• Informant-based rating critical (patient often lacks insight)

3.6 TBI: Cognitive Rehabilitation

Core principles:

1. Neuroplasticity: The brain retains capacity for functional reorganization; rehabilitation exploits this
2. Specificity: Rehabilitation gains are task-specific
3. Intensity and repetition: More practice = stronger new connections
4. Meaningful goals: Patient-centered, functional goals improve motivation and generalization

Domains targeted:

• Attention: Attention Process Training (APT-3)
• Memory: External aids (diaries, smartphones), spaced retrieval, errorless learning
• Executive function: Goal Management Training, Problem-Solving Therapy
• Communication: Speech-language therapy
• Daily living skills: Occupational therapy

Errorless learning (particularly for severe memory impairment):

• Eliminate trial-and-error to prevent encoding of errors
• Relies on implicit memory systems (preserved even in severe amnesia)

Compensatory vs restorative strategies:

• Restorative: Attempt to restore lost function (cognitive exercises)
• Compensatory: Use intact systems to work around deficits (external memory aids)

Cognitive rehabilitation evidence:

• Attention training has best evidence
• Memory strategy training: moderate evidence
• Return to work: vocational rehabilitation programs show benefit

3.7 Aggression Management Post-TBI

Prevalence: 30–50% of moderate-severe TBI survivors; particularly with frontal/temporal damage

Pathophysiology:

• Loss of top-down inhibitory control (PFC → amygdala circuit disrupted)
• Serotonergic dysregulation
• Impaired frustration tolerance
• Pain, sleep deprivation, substance use (comorbid)

Non-pharmacological:

• Cognitive behavior management (CBT for anger)
• Environmental modifications: reduce overstimulation
• Staff education
• Family/caregiver training

Pharmacological:

Avoid: Benzodiazepines (paradoxical disinhibition, impair recovery), typical antipsychotics (dopamine blockade impairs neuroplasticity, haloperidol shown to worsen TBI outcomes in animal models)

3.8 TBI and Substance Use

Bidirectional relationship:

• Pre-injury: Intoxication at time of injury (alcohol in 40–50% of TBI cases)
• Post-injury: Substance use increases after TBI; mechanisms include self-medication (pain, mood, sleep), disinhibition, impaired judgment

Assessment: AUDIT, DAST, validated in TBI populations

Complications:

• Substance use exacerbates neurocognitive deficits
• Increases risk of seizures (alcohol withdrawal)
• Interferes with medications (anticonvulsants, antidepressants)
• Increases re-injury risk

Treatment: Modified MI/CBT for TBI cognitive profile; harm reduction; 12-step programs (adapted); address co-occurring mood/anxiety

3.9 Second Impact Syndrome

Definition: Second impact syndrome (SIS) occurs when an individual sustains a second concussion while still recovering from a previous concussion, leading to catastrophic cerebral swelling.

Mechanism:

• The brain in neurometabolic crisis is vulnerable to loss of vascular autoregulation
• Even a minor second impact → sudden bilateral cerebral swelling → herniation
• Dysautoregulation of cerebrovascular tone → massive vasodilation → malignant edema

Features:

• Typically occurs in young athletes
• Second impact may be trivial (fall, head bump)
• Rapid onset of coma (within minutes)
• Extremely high mortality (~50%) and morbidity
• Prevention: strict "return to play" protocols; DO NOT return to sport until fully asymptomatic from first concussion

SECTION 4: DELIRIUM

4.1 Definition and Core Concepts

Delirium is an acute neuropsychiatric syndrome characterized by:

• Acute onset and fluctuating course
• Inattention (core feature)
• Altered level of arousal OR
• Disorganized thinking (disorientation, cognitive disruption)

It is a medical emergency, always indicates acute brain dysfunction with an underlying cause.

DSM-5 Criteria (Delirium, 293.0):

A. Disturbance in attention (reduced ability to direct, focus, sustain, shift attention) AND awareness (reduced orientation to the environment)

B. Disturbance develops over a short period (hours to days), represents a change from baseline, and tends to fluctuate in severity during the day

C. An additional disturbance in cognition (memory, language, visuospatial, perception)

D. The disturbances are not better explained by another pre-existing neurocognitive disorder, and do not occur in context of severely reduced level of arousal such as coma

E. Evidence from history, physical examination, or lab tests that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to toxin (or combination)

4.2 Confusion Assessment Method (CAM)

The CAM (Inouye et al., 1990) is the most widely used bedside tool for delirium:

Delirium diagnosis = Feature 1 AND Feature 2 AND (Feature 3 OR Feature 4):

1. Acute onset and fluctuating course: Is there evidence of an acute change in mental status from baseline? Does behavior fluctuate during the day?
2. Inattention: Does the patient have difficulty focusing attention (easily distracted, loses track of conversation)?
3. Disorganized thinking: Is thinking disorganized or incoherent (rambling, irrelevant conversation, unclear flow)?
4. Altered level of consciousness: Any level other than alert (vigilant, lethargic, stuporous, comatose)?

Sensitivity: 94–100%; Specificity: 90–95%

CAM-ICU: Modified for non-verbal ICU patients using non-verbal assessment of attention and thinking.

4.3 Delirium Subtypes

Key exam point: Hypoactive delirium is the most common and most often missed subtype. It is often mistaken for depression or simply "being tired." Missed hypoactive delirium → worse outcomes.

4.4 Etiology of Delirium

DELIRIUM Mnemonic for causes:

• D, Drugs (sedatives, anticholinergics, opioids, steroids, antihistamines, polypharmacy)
• E, Eyes/Ears (sensory deprivation)
• L, Low oxygen (hypoxia, PE, pneumonia, heart failure)
• I, Infection (UTI, pneumonia, meningitis, sepsis)
• R, Retention (urinary retention, constipation) / Restraints
• I, Intoxication / Injury (TBI, subdural)
• U, Underhydration / Undernutrition (electrolyte imbalance: Na, Ca, glucose, Mg)
• M, Metabolic (hepatic failure, renal failure, thyroid)

High-risk patient groups:

• Age >70
• Pre-existing dementia (3–5x risk)
• Severe illness / ICU admission
• Post-operative patients (especially cardiac, orthopedic)
• Vision/hearing impairment
• Sleep deprivation
• Pre-existing functional dependence

4.5 Pathophysiology of Delirium

Cholinergic Deficit Hypothesis (most established):

• Acetylcholine is critical for arousal, attention, and REM regulation
• Anticholinergic drugs reliably produce delirium
• High anticholinergic burden correlates with delirium risk
• Physostigmine (acetylcholinesterase inhibitor) reverses some forms of delirium
• Post-operative delirium correlates with central anticholinergic activity in CSF

Neuroinflammation Hypothesis:

• Systemic inflammation (infection, surgery, trauma) → activation of brain microglia
• Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) cross blood-brain barrier or signal via vagus nerve
• Microglial activation → disrupted neurotransmission (DA excess, Ach deficit, GABA changes)
• Elderly brains with existing neurodegeneration have primed microglia → lower threshold for delirium

Dopamine Excess Hypothesis:

• Excess dopaminergic activity (relative to cholinergic) → agitation, psychosis in hyperactive delirium
• Basis for haloperidol (D2 blocker) effectiveness

Other neurotransmitters:

• GABA: over-activity → sedation (benzodiazepine-induced delirium); under-activity → seizures, alcohol withdrawal delirium
• Glutamate: excitotoxicity in severe delirium; NMDA antagonists (ketamine) can cause delirium

Neuroimaging (where available):

• Global cortical hypoperfusion
• Thalamic and prefrontal dysfunction
• Disrupted functional connectivity on fMRI

4.6 Delirium Management

Non-Pharmacological (FIRST LINE: prevents and treats delirium)

HELP Program (Hospital Elder Life Program, Inouye): Multicomponent intervention targeting delirium risk factors:

• Orientation: Clock, calendar, name boards; frequent reorientation by staff
• Mobility: Early mobilization, avoid restraints
• Sleep: Sleep hygiene, non-pharmacological sleep protocols, minimize nighttime interruptions
• Hydration: Ensure adequate fluid intake; IV hydration if needed
• Sensory: Glasses, hearing aids; ensure sensory aids are available
• Cognitive stimulation: Engaging activities, conversations

Evidence: HELP program reduces delirium incidence by 33% and duration by 30–40%.

Pharmacological

Important caveat: No pharmacological agent has FDA approval for delirium treatment or prevention. All use is off-label. Non-pharmacological management remains primary.

Haloperidol:

• Most studied; traditional first choice for hyperactive delirium
• Dose: 0.5–1 mg PO/IM; repeat q4h; titrate
• Advantage: parenteral available; no respiratory depression
• Disadvantage: EPS risk; QTc prolongation; avoid in parkinsonism, Lewy body
• Evidence: Not proven to reduce delirium duration/mortality (HOPE-ICU, MINDS trials)

Quetiapine:

• Preferred in elderly, Lewy body risk, when sedation needed
• Dose: 12.5–25 mg; lower starting dose
• Less EPS; more sedating
• Evidence: Some RCTs showing benefit; not definitive

Olanzapine:

• Effective for agitation; higher metabolic side effects
• IM preparation available for acute agitation

Haloperidol vs Quetiapine in practice:

• Haloperidol = parenteral option, acute severe agitation
• Quetiapine = elderly, Parkinson's-adjacent, less EPS needed

Dexmedetomidine (ICU setting):

• Alpha-2 agonist; promotes physiological sleep architecture
• Better outcomes than benzodiazepines in ICU delirium
• Evidence from MENDS2 and MIDEX trials

Melatonin / Ramelteon:

• For delirium prevention, especially sleep disruption component
• Ramelteon 8mg at bedtime: reduced delirium incidence in RCT (Hatta et al., 2014)

AVOID:

• Benzodiazepines (except alcohol withdrawal delirium, seizures, where they are indicated)
• Physostigmine: only for anticholinergic toxidrome reversal
• Restraints: worsen delirium by increasing agitation and anxiety

4.7 Delirium Tremens (DTs)

Covered in detail in NB-08 (Substance Use Disorders). Key cross-reference points:

• DTs occur 48–72 hours after last alcohol use
• Life-threatening: mortality 5–15% if untreated; <1% with treatment
• Treatment: benzodiazepines (diazepam, lorazepam, chlordiazepoxide) via CIWA-Ar guided protocol
• Thiamine BEFORE glucose
• Signs: autonomic instability (HR, BP, temp, sweating), seizures, hallucinations (typically visual)
• Prophylaxis: CIWA-Ar protocol for high-risk patients
• Wernicke's encephalopathy triad: ataxia, ophthalmoplegia, confusion, treat with IV thiamine 100–500 mg TID

4.8 Delirium vs Dementia

4.9 Delirium Superimposed on Dementia (DSD)

• Most clinically challenging scenario
• Patients with dementia have 3–5x higher risk of delirium
• Hypoactive delirium is most common and most missed
• Distinguishing DSD from dementia progression: look for acuity of change, fluctuation, new somatic trigger
• Key tool: DOSS (Delirium Observation Screening Scale) for nurses; Nu-DESC
• Management: address acute trigger; minimize anticholinergic burden; re-establish orientation cues
• Long-term consequences of DSD: accelerated cognitive decline, increased mortality, faster dementia progression

SECTION 5: AMNESTIC DISORDERS

5.1 Classification of Amnestic Disorders

Amnestic disorders are characterized by memory impairment as the predominant cognitive deficit, without the broader cognitive deficits of dementia.

DSM-5: "Amnestic Disorder Due to Another Medical Condition" or "Substance-Induced Persisting Amnestic Disorder"

Types of memory affected:

• Anterograde amnesia: Cannot form new memories after the causative event (implicit/procedural memory relatively preserved, uses different systems)
• Retrograde amnesia: Loss of memories from before the causative event; often follows a temporal gradient (Ribot's Law: recent memories lost first, remote memories preserved longer)

5.2 Korsakoff's Syndrome (Amnestic Confabulatory Syndrome)

Etiology: Thiamine (Vitamin B1) deficiency, most commonly due to chronic alcoholism; also: prolonged vomiting (hyperemesis, bariatric surgery), malnutrition, total parenteral nutrition without thiamine supplementation

Neuropathology:

• Bilateral hemorrhagic lesions in periventricular and periaqueductal gray matter
• Mammillary bodies, atrophied (characteristic on MRI; pathognomonic)
• Medial dorsal thalamus (most important for amnesia)
• Anterior thalamic nuclei
• Fornix white matter

Clinical Features:

• Dense anterograde amnesia (cannot form new memories)
• Retrograde amnesia (variable; follows Ribot's Law)
• Confabulation: Fabrication of information to fill memory gaps; patient has no insight that confabulations are false, provoked confabulation (answering questions with fabricated responses) vs spontaneous confabulation (unprompted false memories)
• Relative preservation of: Procedural memory, working memory, social/emotional memory
• Apathy, flatness of affect
• Perseveration
• Disorientation (especially temporal, cannot track date/time)

Relationship to Wernicke's Encephalopathy:

• Wernicke's encephalopathy (WE) = acute thiamine deficiency crisis
• Classic triad: Confusion + Ataxia + Ophthalmoplegia (nystagmus, lateral rectus palsy, conjugate gaze palsy)
• Only ~16% present with full triad
• WE → Korsakoff's if thiamine not replaced promptly (20–80% of untreated WE → Korsakoff's)
• "Wernicke-Korsakoff Syndrome" = continuum

Treatment:

• Thiamine replacement: IV 200–500 mg TID (Pabrinex) for acute WE
• ALWAYS give thiamine BEFORE glucose (glucose administration without thiamine can precipitate WE in thiamine-deficient patients)
• Korsakoff's: many do not fully recover; some improvement with abstinence and thiamine
• Long-term: supported accommodation, external memory aids, supervised living

5.3 Transient Global Amnesia (TGA)

Definition: A syndrome of sudden-onset, transient anterograde amnesia lasting up to 24 hours, with preserved personal identity and consciousness.

Epidemiology: Middle-aged to elderly (50–70 years); annual incidence 5–10/100,000

Clinical Features:

• Abrupt onset
• Dense anterograde amnesia, cannot form new memories
• Repetitive stereotyped questioning ("Where are we? What are we doing here?"), pathognomonic
• Preserved personal identity (unlike dissociative amnesia)
• No focal neurological deficits
• Normal level of consciousness
• Retrograde amnesia for hours before and during the episode
• Resolves completely within 24 hours (by definition)
• No delirium, no seizure activity

Precipitants:

• Physical exertion
• Sexual intercourse
• Valsalva maneuver
• Cold water immersion
• Emotional stress
• Migraine

Pathophysiology: Unclear; hypotheses include:

• Transient ischemia to hippocampal-thalamic circuit (posterior circulation)
• Cortical spreading depression (migraine-like mechanism)
• Venous congestion with Valsalva → transient hippocampal ischemia

Investigations:

• MRI DWI: small diffusion restriction spots in CA1 region of hippocampus (seen on MRI 24–48 hours after; Sedlaczek phenomenon)
• EEG: normal (differentiates from transient epileptic amnesia)
• Duplex ultrasound: check for venous insufficiency

Prognosis: Recurrence ~6% per year; low risk of stroke; benign condition

No treatment required

Differential: Transient Epileptic Amnesia (TEA), shorter episodes (<1 hour), recurrent, associated with post-ictal confusion, responds to anticonvulsants

5.4 Hippocampal Pathology and Amnesia

Bilateral hippocampal damage → anterograde amnesia:

• Classic case: HM (Henry Molaison), bilateral hippocampectomy for epilepsy; dense anterograde amnesia, intact procedural memory, intact remote memories
• Damage to CA1 subfield most critical (vulnerable to ischemia, excitotoxicity)

Unilateral hippocampal damage:

• Left hippocampus: verbal memory (story recall, word lists)
• Right hippocampus: non-verbal memory (faces, spatial routes)

Causes of bilateral hippocampal damage:

• Anoxia (cardiac arrest)
• Herpes simplex encephalitis (HSE), HSV-1; necrotizing encephalitis of medial temporal and orbitofrontal regions; MRI: bilateral temporal signal change; Treatment: acyclovir
• Status epilepticus
• Autoimmune encephalitis (anti-NMDAR, anti-LGI1)
• Thiamine deficiency (Korsakoff's, hippocampal and diencephalic)
• Severe hypoglycemia

5.5 Organic vs Dissociative Amnesia

SECTION 6: NEUROPSYCHIATRIC ASSESSMENT

6.1 Bedside Cognitive Testing

6.1.1 Mini-Mental State Examination (MMSE)

Total: 30 points

Domains: Orientation (10), Registration (3), Attention/Calculation (5), Recall (3), Language (8), Visuoconstructional (1)

Score interpretation:

• 24–30: Normal
• 18–23: Mild impairment
• 12–17: Moderate impairment
• <12: Severe impairment

Limitations: Ceiling effect for higher education; floor effect for severe dementia; poor sensitivity for frontal/subcortical deficits; language-dependent; not diagnostic

6.1.2 Montreal Cognitive Assessment (MoCA)

Total: 30 points (add 1 if <12 years education)

Domains: Visuospatial/executive (5), Naming (3), Memory (5), Attention (6), Language (3), Abstraction (2), Delayed recall (5), Orientation (6)

Cut-off: <26 = cognitive impairment

Advantages over MMSE: Better at detecting MCI; tests frontal/executive function; more sensitive for subtle deficits

6.1.3 Addenbrooke's Cognitive Examination-III (ACE-III)

Total: 100 points

Cut-off: <82 for dementia screening; <88 if high education

Advantages: Better discrimination between dementia subtypes; high sensitivity; verbal fluency and visuospatial detail

6.2 Frontal Lobe Tests (Bedside)

Go-No-Go Test

Examiner taps once = patient taps once; Examiner taps twice = patient does NOT tap

Frontal impairment: Patient taps regardless of stimulus (response inhibition failure, OFC)

Luria Motor Series (fist-edge-palm)

Patient sequences three hand positions repeatedly

Frontal impairment: Cannot maintain sequence; perseverates; simplifies

Verbal Fluency (FAS / Animals / Professions)

• Phonemic fluency (FAS): Name words starting with F, A, S (1 minute each), normal >12–15 per letter
• Semantic fluency (animals): Name animals in 1 minute, normal >15
• Frontal impairment affects phonemic > semantic fluency

Alternating Sequences

Draw alternating MWMWMW on paper and ask patient to continue

Frontal impairment: perseverates on one shape (M or W repeatedly)

Frontal Assessment Battery (FAB): full scoring

Already described in 2.1.4

6.3 Visuospatial Assessment

• Clock Drawing Test (CDT): Draw clock, set hands to 11:10, tests planning, visuospatial, executive; impaired in parietal, frontal, subcortical
• Rey Complex Figure Test (RCFT): Copy complex figure; recall after 3 minutes and 30 minutes; tests visuospatial organization and memory
• Copying pentagons: MMSE item; impaired in cortical dementias
• Trail Making Test A and B: TMT-A = attention/processing speed; TMT-B = set-shifting/executive

6.4 Language Assessment

• Spontaneous speech: Fluent vs non-fluent (pitch, rate, effort, paraphasia)
• Naming: Boston Naming Test; bedside: name pen, watch, parts of pen
• Repetition: "No ifs, ands, or buts", tests arcuate fasciculus
• Comprehension: Follow 3-step command; point to objects named
• Reading, Writing: Alexia, agraphia

Aphasia types:

SECTION 7: BRAIN TUMORS AND PSYCHIATRY

7.1 General Principles

Brain tumors cause psychiatric symptoms via:

1. Direct compression/infiltration of brain regions (location-specific)
2. Raised intracranial pressure (ICP), cognitive slowing, personality change
3. Seizure activity, ictal/postictal psychiatric symptoms
4. Paraneoplastic effects, autoimmune encephalitis
5. Systemic effects, metabolic, endocrine, medication-related

Important principle: New-onset psychiatric symptoms in middle-aged/elderly patients, especially atypical presentations or those with neurological signs, require neuroimaging.

7.2 Frontal Meningioma

Location: Parasagittal, convexity, sphenoidal, olfactory groove (anterior fossa)

Classic presentation:

Olfactory groove meningioma:

• Anosmia (unilateral, then bilateral), often not noticed by patient
• Frontal lobe psychiatric symptoms: personality change, apathy, disinhibition
• Foster Kennedy Syndrome: ipsilateral optic atrophy + contralateral papilledema (tumor compresses one optic nerve; raises ICP causing papilledema on other side)
• Psychiatric presentation: depression, personality change, early cognitive decline, can be mistaken for primary psychiatric illness or early dementia for years

Parasagittal/convexity meningioma:

• Often presents with seizures
• Contralateral motor deficit
• Personality change if near frontal lobe

Key exam scenario: Middle-aged woman (meningiomas are more common in females, F:M = 2:1) with gradual personality change, frontal release signs, anosmia → imaging reveals frontal meningioma

7.3 Temporal Glioma

Presentation:

• Seizures, temporal lobe seizures with automatisms, olfactory/gustatory auras, deja vu, jamais vu
• Psychiatric presentation: anxiety, mood changes, psychosis (if temporal lobe dysfunction)
• Memory impairment: especially with dominant (left) temporal involvement
• Personality changes: if extending to medial temporal/amygdala

Low-grade glioma: may present with psychiatric symptoms years before mass effect (diagnosis often delayed)

7.4 Pituitary Tumors (Adenomas)

Location: Sella turcica; extends into suprasellar region

Neurological effects:

• Bitemporal hemianopia (compression of optic chiasm), tunnel vision
• Headache (dural stretch)
• Cavernous sinus involvement: cranial nerve palsies (III, IV, VI)

Psychiatric effects via hormonal excess:

• Cushing's disease (ACTH-secreting): Depression (most common), anxiety, cognitive impairment; frank psychosis in ~5%; cortisol toxicity to hippocampus → memory impairment
• Prolactinoma: Sexual dysfunction, depression (hyperprolactinemia → hypogonadism → mood effects); treated with dopamine agonists (cabergoline, bromocriptine)
• Acromegaly (GH-secreting): Depression, anxiety, fatigue
• Non-functioning adenoma: Cognitive slowing, depression from mass effect; hypogonadism from stalk compression → depression/fatigue

Treatment:

• Cushing's: surgery (transsphenoidal), ketoconazole, mifepristone; psychiatric symptoms often improve with cortisol normalization
• Prolactinoma: cabergoline first line; surgery if not responding
• Monitor: psychiatric symptoms may persist even after successful endocrine treatment (HPA axis normalization takes time)

SECTION 8: NEUROPSYCHIATRIC ASPECTS OF COVID-19

8.1 Acute Phase

CNS invasion pathways:

• Direct neurotropism (via ACE2 receptors on neurons/glia, limited evidence)
• Hematogenous spread
• Retrograde axonal transport via olfactory nerve (anosmia → direct brain access)
• Neuroinflammation, cytokine storm → blood-brain barrier disruption → microglial activation

Acute neuropsychiatric presentations:

• Delirium: most common in hospitalized/ICU patients; up to 50% in severe COVID ICU
• Stroke: coagulopathy (hypercoagulability), cardioembolism
• Encephalitis (rare): anti-NMDAR antibodies reported
• Acute disseminated encephalomyelitis (ADEM), rare
• Myelin oligodendrocyte glycoprotein antibody disease (MOGAD), rare

8.2 Post-COVID-19 Neuropsychiatric Syndrome ("Long COVID" / "Post-Acute Sequelae of COVID-19: PASC")

Prevalence: 10–30% of COVID-19 survivors experience prolonged symptoms

Neuropsychiatric symptoms:

• "Brain fog": Difficulty concentrating, word-finding problems, slowed processing
• Fatigue, most prevalent; can be disabling
• Depression and anxiety, both reactive and possibly neurobiologically mediated
• Sleep disturbance, insomnia, hypersomnia, circadian dysregulation
• PTSD, especially after ICU admissions; vivid nightmares, hyperarousal
• Headache, tension-type, migrainous
• Anosmia/parosmia, may persist months; linked to olfactory bulb damage

Mechanisms:

• Neuroinflammation, persistent microglial activation; cytokine dysregulation
• Autoimmune, autoantibodies against ACE2, GPCRs, platelet-activating factor
• Vascular, persistent microthrombi, endothelial dysfunction
• Mitochondrial dysfunction, reduced ATP production → fatigue, cognitive impairment
• HPA axis dysregulation, stress response
• Gut-brain axis, COVID impacts gut microbiome; dysbiosis → neuropsychiatric symptoms

Neuroimaging findings (research):

• Reduced gray matter in olfactory and parahippocampal cortex (Douaud et al., Nature 2022)
• White matter microstructure changes
• Hypometabolism on FDG-PET in fronto-parietal regions

Management:

• No disease-specific treatment proven
• Symptom-directed management
• Cognitive rehabilitation for brain fog
• CBT for fatigue, anxiety, PTSD
• Sleep hygiene, graded exercise (with caution in ME/CFS-like cases)
• Multidisciplinary approach (neurology, psychiatry, physiotherapy, occupational therapy)

SECTION 9: SPECIAL TOPICS

9.1 Neuropsychiatric Assessment: Integrated Approach

Structured approach to organic psychiatric presentations:

Step 1, History

• Onset: Acute (delirium, stroke, TBI) vs subacute (tumor, encephalitis) vs chronic (dementia, VCI)
• Course: Fluctuating (delirium), stepwise (VCI), progressive (dementia)
• Temporal relationship between neurological event and psychiatric symptoms
• Pre-morbid personality and cognitive level (crucial baseline)
• Medical/surgical history, medications, substance use
• Family history of neurological/psychiatric conditions

Step 2, Mental State Examination (modified for organic)

• Level of consciousness and arousal
• Orientation: time, place, person, date
• Attention: forward/reverse digit span; months of year backwards
• Memory: registration, recall (3-word or 5-word test)
• Executive function: verbal fluency, abstraction
• Frontal signs: FAB if time permits
• Perceptual disturbances: visual hallucinations (organic), auditory hallucinations (psychiatric but also organic)
• Speech and language

Step 3, Neurological Examination

• Cranial nerve examination
• Motor system: power, tone, reflexes (hyperreflexia = UMN)
• Primitive reflexes: grasp, palmomental, snout, glabellar tap
• Cerebellar: ataxia, nystagmus, dysarthria
• Gait: Parkinson's gait, normal pressure hydrocephalus gait (magnetic, broad-based, urinary incontinence, dementia)

Step 4, Investigations

• Basic bloods: FBC, CRP, ESR, U&E, creatinine, glucose, LFTs, TFTs, calcium, phosphate, B12, folate
• Urinalysis: UTI (common delirium cause in elderly)
• Neuroimaging: CT head (acute stroke, hemorrhage, mass); MRI (white matter disease, hippocampal atrophy, temporal lesions)
• EEG: Delirium (generalized slowing), epilepsy, encephalitis (PLEDS, FIRDA)
• LP: Encephalitis, meningitis, autoimmune encephalitis (CSF pleocytosis, oligoclonal bands)
• Autoimmune panel: Anti-NMDAR, anti-LGI1, anti-CASPR2, anti-AMPAR antibodies
• Neuropsychological testing: Formal assessment if bedside screening insufficient

9.2 Normal Pressure Hydrocephalus (NPH)

Classic triad (Hakim's triad):

1. Wet, urinary incontinence
2. Wobbly, gait apraxia (magnetic gait: small steps, feet "stuck to floor," wide-based)
3. Wacky, cognitive impairment (subcortical: executive, memory)

Neuroimaging: CT/MRI, ventriculomegaly out of proportion to sulcal atrophy; Evans index >0.3

Diagnosis: LP with high-volume CSF removal (30–50 mL) → gait improvement (positive tap test)

Treatment: Ventriculoperitoneal (VP) shunting, most effective for gait and incontinence; cognitive improvement variable

9.3 Autoimmune Encephalitis

Key antibodies:

• Anti-NMDAR encephalitis: Most common; young women; associated with ovarian teratoma; psychiatric presentation first (psychosis, behavioral change) → seizures → movement disorders → autonomic instability → coma
• Anti-LGI1 encephalitis: Older males; faciobrachial dystonic seizures (FBDS); hyponatremia; memory problems
• Anti-CASPR2: Morvan's syndrome (neuromyotonia, encephalopathy); associated with thymoma
• Anti-AMPAR: Limbic encephalitis; memory and mood disturbance
• Anti-GABA-B: Limbic encephalitis; seizures prominent

General presentation: Subacute onset; combination of psychiatric symptoms + seizures + movement abnormalities + autonomic features

Investigations: MRI (temporal lobe T2/FLAIR signal); EEG (delta brush pattern in anti-NMDAR); CSF (pleocytosis, protein elevation); serum and CSF antibodies

Treatment: Immunotherapy, first line: IV methylprednisolone + IVIG ± plasma exchange; second line: rituximab, cyclophosphamide; tumor removal if paraneoplastic

Psychiatric relevance: Anti-NMDAR presents as acute psychosis in young patients → often initially treated as schizophrenia → diagnosis delayed → outcomes worsened. Must consider autoimmune encephalitis in new-onset psychosis, especially with fever, seizures, movement abnormalities, or rapid progression.

9.4 Epilepsy and Psychiatry (Brief Overview: Detailed in NB-15)

Interictal psychosis (Schizophrenia-like psychosis of epilepsy, SLPE):

• Occurs in temporal lobe epilepsy
• Chronic psychosis with preserved affect (vs blunted affect in schizophrenia)
• Onset after 10–15 years of epilepsy
• Positive symptoms predominant

Postictal psychosis:

• After cluster seizures, lucid interval of 24–72 hours
• Then psychosis (often manic/mixed features, aggression)
• Resolves spontaneously in days to weeks

Forced normalization / Paradoxical normalization / Landolt's phenomenon:

• Psychiatric symptoms (psychosis, hypomania) emerge when seizures are controlled (EEG normalizes)
• Discontinuing anticonvulsant or reducing it may paradoxically help psychosis

Antipsychotics and seizure threshold: Clozapine and chlorpromazine lower seizure threshold most; risperidone, haloperidol relatively safe; quetiapine intermediate

SECTION 10: RAPID-FIRE EXAM POINTS

High-Yield One-Liners

• Robinson hypothesis: left anterior frontal lesion → highest rates of PSD
• PSD prevalence: 30–50% overall; peaks at 3–6 months post-stroke
• First-line PSD treatment: sertraline or fluoxetine
• PBA treatment: dextromethorphan/quinidine (Nuedexta), first FDA-approved treatment
• PBA mechanism: damage to corticobulbar pathways → release of brainstem motor-emotional circuits
• Anosognosia: right parietal lesion; patient unaware of left hemiplegia
• Post-stroke mania: right hemisphere; basal temporal, OFC, caudate
• Apathy vs depression: apathy = no distress, neutral mood; depression = distress, dysphoria
• CAM criteria: 1+2+(3 or 4), Acute onset, Inattention, Disorganized thinking, Altered arousal
• Hypoactive delirium: most common, most missed; worst prognosis
• Delirium pathophysiology: cholinergic deficit + neuroinflammation + dopamine excess
• Korsakoff's: mammillary body + medial dorsal thalamus lesions; confabulation
• Give thiamine BEFORE glucose in suspected Wernicke's
• TGA: repetitive questioning, lasts <24 hrs, no focal neurology, benign
• CTE: posthumous diagnosis; tau deposits perivascular; associated with repetitive TBI
• Moderate TBI: GCS 9–12; PTA 1–7 days
• Second impact syndrome: young athletes; catastrophic cerebral swelling; 50% mortality
• Propranolol: best evidence for aggression post-TBI
• OFC lesion = pseudopsychopathic syndrome (Phineas Gage)
• DLPFC lesion = pseudodepression (flat affect, executive dysfunction)
• Olfactory groove meningioma: anosmia + frontal psychiatric symptoms + Foster Kennedy syndrome
• Cushing's disease: depression most common psychiatric manifestation; cortisol toxic to hippocampus
• Anti-NMDAR encephalitis: young women, ovarian teratoma, psychiatric onset, NMDA receptor antibodies
• NPH triad: Wet + Wobbly + Wacky
• Gerstmann syndrome: finger agnosia, L-R disorientation, agraphia, acalculia → left angular gyrus
• CADASIL: NOTCH3 mutation; hereditary subcortical vascular dementia + migraine
• Long COVID neuropsychiatric: brain fog, fatigue, PTSD, depression; mechanism = neuroinflammation

Word count: ~15,500

Model Answers

Answer 1: Post-Stroke Depression: Etiology, Prevalence, and Management

[10 marks, Long Answer]

Introduction

Post-stroke depression (PSD) is the most common neuropsychiatric complication of stroke, affecting 30–50% of survivors. It is classified in DSM-5 as Depressive Disorder Due to Another Medical Condition (Stroke). PSD significantly worsens functional outcomes, delays rehabilitation, and increases mortality.

Prevalence

• Lifetime prevalence: 30–50% of stroke survivors
• Acute phase (0–2 weeks): ~25–30%
• Peak at 3–6 months post-stroke: ~35%
• Community studies suggest ~20–25% at one year
• Depression is more severe and more prevalent in hospital-based samples (selection bias)

Etiology: Multifactorial Model

1. Neurobiological (Robinson's Left Frontal Hypothesis)

Robinson and colleagues (1984, 1987) proposed that:

• Lesions of the left anterior frontal cortex, specifically left dorsolateral prefrontal cortex (DLPFC) and left basal ganglia, produce the highest rates and most severe depression after stroke.
• Mechanism: Left hemisphere damage disrupts descending serotonergic and noradrenergic projections from the frontal cortex through fronto-striato-thalamo-cortical circuits to the limbic system.
• The left hemisphere normally regulates approach-related positive affect. Its disruption results in unopposed negative affect (right hemisphere).
• Lesion-to-frontal-pole distance (on CT) inversely correlates with depression severity for left hemisphere strokes.
• Critiques: Meta-analyses found lateralization effect strongest in hospital-based, acute samples. Community studies less consistent. Current consensus: left frontal relationship is real but not absolute.

2. Neurochemical Factors

• Depletion of biogenic amines (serotonin, noradrenaline, dopamine) in fronto-limbic pathways disrupted by infarct
• HPA axis dysregulation, cortisol elevation with hippocampal atrophy
• Neuroinflammatory cascades (IL-1β, IL-6) alter neurotransmitter turnover

3. Psychosocial Factors

• Pre-stroke depression or anxiety (strongest psychosocial predictor)
• Degree of functional disability (ADL dependence)
• Social isolation, poor social support
• Loss of occupational roles and identity
• Fear of recurrence, grief response to disability

4. Genetic/Premorbid Factors

• Personal/family history of depression
• Serotonin transporter gene polymorphisms (5-HTTLPR)
• Female sex
• Cognitive impairment

Clinical Features

• Overlaps with primary MDD but notable differences:
• More prominent apathy (overlapping syndrome, must distinguish)
• More neurovegetative features (fatigue, sleep disruption) confounded by stroke itself
• Emphasis on cognitive-affective symptoms: anhedonia, hopelessness, worthlessness, suicidal ideation
• Emotional lability frequently co-occurs
• Assessment tools: MADRS (preferred, less somatic items), PHQ-9, GDS, HDRS

Management

A. Pharmacological

Swipe to compare →

• Duration: minimum 6–12 months after response; relapse common with early cessation
• Prophylaxis: Sertraline/escitalopram trial for high-risk patients (left frontal, prior depression), mixed evidence

B. Non-Pharmacological

• CBT (modified for cognitive deficits/aphasia), good evidence
• Problem-solving therapy
• Exercise (aerobic, 3–5× per week), RCT evidence
• Social support interventions
• Motivational interviewing for adherence
• Caregiver psychoeducation

Prognosis

• Untreated PSD doubles disability and mortality risk
• Treatment response is generally good (60–70% respond to antidepressants)
• Persistent PSD (>1 year) associated with worse functional outcomes
• Late-onset PSD (>6 months) more strongly linked to psychosocial factors

Answer 2: Delirium: Classification, Diagnosis, and Management

[10 marks, Long Answer]

Definition

Delirium is an acute, potentially reversible neuropsychiatric syndrome characterized by disturbances in attention, awareness, and cognition, with an acute onset and fluctuating course. It is always caused by an identifiable medical/toxic/metabolic etiology. It constitutes a neurological emergency.

DSM-5 Diagnostic Criteria

Criterion A: Disturbance in attention (reduced ability to direct, focus, sustain, shift attention) and awareness (reduced environmental orientation).

Criterion B: Acute onset (hours to days), change from baseline, tendency to fluctuate during the day.

Criterion C: Additional cognitive disturbance (memory deficit, disorientation, language, visuospatial, or perceptual disturbance).

Criterion D: Not explained by established NCD; not occurring during markedly reduced arousal (e.g., coma).

Criterion E: Direct physiological consequence of medical condition, substance intoxication/withdrawal, toxin exposure, or combination.

Classification by Subtype

Bedside Diagnosis: CAM

Confusion Assessment Method (Inouye, 1990):

Delirium = Feature 1 AND Feature 2 AND (Feature 3 OR Feature 4)

1. Acute onset + fluctuating course
2. Inattention (digit span, months backwards)
3. Disorganized thinking
4. Altered level of consciousness

Sensitivity 94–100%; Specificity 90–95%

CAM-ICU: Non-verbal variant for intubated patients (uses RASS + visual attention tests)

Etiology

DELIRIUM Mnemonic:

• D, Drugs (opioids, benzodiazepines, anticholinergics, steroids)
• E, Eyes/Ears (sensory deprivation)
• L, Low oxygen (pneumonia, PE, cardiac failure)
• I, Infection (UTI, sepsis, meningitis)
• R, Retention (urinary retention, constipation) / Restraints
• I, Intoxication or Injury (TBI, subdural hematoma)
• U, Underhydration / electrolytes (Na, Ca, glucose, Mg)
• M, Metabolic (hepatic failure, renal failure, thyroid)

Pathophysiology

1. Cholinergic Deficit Hypothesis:

• Acetylcholine critical for arousal, attention, REM regulation
• Anticholinergic drugs reliably cause delirium
• Physostigmine reverses anticholinergic delirium

2. Neuroinflammation:

• Systemic inflammation → activated microglia → pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) → BBB disruption → neurotransmitter dysregulation

3. Dopamine Excess:

• Relative excess of dopamine (vs acetylcholine) → hyperactive features
• Basis for antipsychotic (D2 blocker) use

4. Other neurotransmitters: GABA over-activity (benzodiazepines), glutamate excess (excitotoxicity)

Management

A. Non-Pharmacological (First Line)

HELP Program (Hospital Elder Life Program, Inouye):

• Orientation aids: clock, calendar, name boards
• Early mobilization; avoid restraints
• Sleep hygiene: dimmed lights at night, no nighttime vitals unless necessary
• Hydration: oral or IV
• Sensory aids: glasses, hearing aids
• Cognitive stimulation during daytime

Evidence: Reduces incidence by 33%, duration by 30–40%

B. Pharmacological (Adjunct, no FDA approval for delirium)

• Haloperidol 0.5–1 mg PO/IM q4h: Most evidence; parenteral option; risk EPS, QTc
• Quetiapine 12.5–25 mg: Preferred in elderly, Lewy body risk, Parkinson's; sedating
• Olanzapine 2.5–5 mg: IM available for acute agitation
• Dexmedetomidine (ICU): Alpha-2 agonist; better than benzodiazepines in ICU delirium (MENDS2, MIDEX trials)
• Ramelteon 8 mg at bedtime: Reduces incidence in at-risk patients (prevention)

AVOID: Benzodiazepines (except alcohol withdrawal); physical restraints

Delirium vs Dementia

Answer 3: Traumatic Brain Injury: Classification, Psychiatric Sequelae, and Management

[10 marks, Long Answer]

Definition

Traumatic brain injury (TBI) is defined as an alteration in brain function caused by an external mechanical force. It may be open (penetrating) or closed (blunt). Severity is classified by Glasgow Coma Scale (GCS) score.

GCS-Based Classification

GCS = Eye (4) + Verbal (5) + Motor (6); Total 3–15

Additional markers: CT/MRI findings (contusion, DAI, hemorrhage), biomarkers (GFAP, S100B, NSE)

Psychiatric Sequelae

A. Acute Phase

• Post-traumatic delirium/confusion (universal in moderate-severe TBI)
• Agitation (up to 70% in ICU)
• Post-traumatic amnesia (PTA), duration predicts outcome

B. Subacute / Chronic

1. Post-Concussion Syndrome (PCS), Mild TBI

• Headache, dizziness, cognitive slowing, fatigue, irritability, sleep disturbance, anxiety
• ICD-10: F07.2; DSM-5: Mild NCD due to TBI
• Risk factors: Female, pre-existing anxiety/headache, prior concussion, health anxiety
• 80–90% resolve in 7–10 days; 10–20% develop PCS; <5% persist beyond 1 year
• Management: Graded return to activity; symptom-specific treatment; CBT for psychological component

2. Personality Change Due to TBI (DSM-5 Subtypes)

• Labile type: affective instability
• Disinhibited type: impulsivity, OFC damage
• Aggressive type: irritability, frontal + temporal
• Apathetic type: frontal/ACC damage
• Prevalence: 50–80% of moderate-severe TBI

3. Depression Post-TBI

• Prevalence: 25–50%
• Associated with premorbid depression, left frontal damage, cognitive impairment
• Treatment: SSRIs (sertraline, citalopram); TCA caution (seizure risk)

4. Anxiety Post-TBI

• PTSD (15–25%): Re-experiencing, avoidance, hyperarousal
• GAD pattern common
• Treatment: Trauma-focused CBT (TF-CBT), EMDR, SSRIs

5. Psychosis Post-TBI

• 2–8% of moderate-severe TBI
• Temporal lobe damage, frontal-limbic disconnection
• Treat with low-dose atypical antipsychotics (avoid haloperidol, impairs recovery)

6. Chronic Traumatic Encephalopathy (CTE)

• Repetitive TBI → hyperphosphorylated tau accumulation (perivascular, sulcal depths)
• Posthumous diagnosis; stages I–IV
• Features: depression, explosivity, memory loss, Parkinsonism
• No specific treatment; posthumous pathological diagnosis

C. Aggression Post-TBI

• Pharmacological: Propranolol (best evidence), SSRIs, valproate, buspirone, amantadine
• Avoid benzodiazepines (paradoxical disinhibition) and haloperidol (impairs neuroplasticity)

Cognitive Rehabilitation

Principles: Neuroplasticity, specificity, intensity, meaningful goals

• Attention: Attention Process Training (APT-3)
• Memory: External aids, errorless learning, spaced retrieval
• Executive function: Goal Management Training
• Evidence: Strongest for attention training; moderate for memory strategies

Answer 4: Korsakoff's Syndrome: Etiology, Clinical Features, Pathology, and Treatment

[8 marks]

Introduction

Korsakoff's syndrome is a chronic amnestic disorder resulting from thiamine (Vitamin B1) deficiency, most commonly in the context of chronic alcohol use disorder. It often follows acute Wernicke's encephalopathy and constitutes the chronic pole of the Wernicke-Korsakoff continuum.

Etiology

• Thiamine deficiency: Primary cause; chronic alcoholism (impaired absorption + poor dietary intake + hepatic dysfunction)
• Non-alcoholic causes: Hyperemesis gravidarum, prolonged vomiting, bariatric surgery, total parenteral nutrition without thiamine supplementation, malnutrition, HIV/AIDS, refeeding syndrome

Neuropathology

Sites of hemorrhagic/necrotic lesions (bilateral):

• Mammillary bodies, atrophied; visible on MRI; pathognomonic; part of Papez circuit
• Medial dorsal thalamus, most critical site for amnesia (mediodorsal thalamic nuclei)
• Anterior thalamic nuclei
• Periaqueductal gray matter
• Floor of fourth ventricle
• Fornix white matter

Note: Hippocampus relatively spared in Korsakoff's (distinguishes from hypoxic amnesia)

Clinical Features

Core features:

1. Dense anterograde amnesia, cannot form new memories; inability to lay down episodic memories; implicit/procedural memory preserved
2. Retrograde amnesia, temporal gradient (Ribot's Law: recent memories lost first, remote memories preserved longer); variable severity
3. Confabulation, fabrication to fill memory gaps; patient has no awareness of falseness:
4. Provoked confabulation: In response to direct questions
5. Spontaneous confabulation: Unprompted false narratives (associated with additional frontal damage)
6. Apathy and flatness of affect, reduced emotional responsiveness
7. Disorientation, particularly temporal; cannot track date/day accurately
8. Relatively preserved: Social skills, procedural memory, working memory, remote memories (variable)

Wernicke's triad (acute preceding phase):

• Confusion (global confusional state)
• Ataxia (cerebellar gait)
• Ophthalmoplegia (nystagmus, lateral rectus palsy, conjugate gaze palsy)
• Full triad present in only ~16%; any one component warrants thiamine treatment

Treatment

Acute Wernicke's:

• IV thiamine (Pabrinex): 200–500 mg TID for 3–5 days
• CRITICAL: Thiamine BEFORE glucose administration (glucose without thiamine precipitates acute WE in deficient patients)
• Subsequent oral thiamine supplementation

Chronic Korsakoff's:

• Continued thiamine supplementation
• Abstinence from alcohol
• Approximately 20–30% make full recovery; 50% partial recovery; 25% no improvement
• External memory aids (diaries, smartphones, structured timetables)
• Supervised/supported living arrangements
• Occupational therapy for functional independence

Answer 5: Pseudobulbar Affect (Emotional Incontinence): Features, Mechanism, and Treatment

[6 marks]

Definition

Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, uncontrollable episodes of laughing or crying (or both) that are incongruent with the patient's subjective emotional state. Also termed: pathological laughing and crying (PLC), emotional lability, or emotional incontinence.

Clinical Features

• Episodes are sudden, brief (seconds to minutes), and self-terminating
• Often incongruent: patient may cry without feeling sad; laugh without amusement
• Patient is typically aware the reaction is excessive and feels embarrassed
• Episodes can be triggered by minor stimuli or occur spontaneously
• No alteration of consciousness
• Frequency: multiple times per day in severe cases

Associated neurological conditions:

• Stroke (most common)
• Traumatic brain injury
• Amyotrophic lateral sclerosis (ALS)
• Multiple sclerosis
• Parkinson's disease / Parkinsonism
• Dementias (especially multi-infarct dementia)

Mechanism

• Loss of voluntary cortical inhibition over brainstem motor-emotional circuits (pontine-cerebellar pathways)
• Descending corticobulbar fibers normally exert tonic inhibition on brainstem emotional expression centers
• Damage to these fibers → involuntary release of emotional expression
• Neurotransmitter basis: Serotonin (regulatory); glutamate/NMDA receptor dysregulation; sigma-1 receptor modulation

Differential Diagnosis

• Labile mood (bipolar): Full mood episodes; control is preserved
• Ictal laughter (gelastic seizures): Prolonged, stereotyped, associated with other ictal signs; EEG abnormal
• Major depression with crying: Congruent with sad mood; not involuntary
• Adjustment disorder: Congruent with stressor; voluntary control present

Assessment: CNS-LS (Center for Neurologic Study, Lability Scale)

Treatment

Pharmacological:

1. Dextromethorphan/Quinidine (Nuedexta), FDA-approved 2010; first disease-specific treatment
2. Mechanism: Quinidine inhibits CYP2D6 → raises dextromethorphan levels
3. Dextromethorphan: sigma-1 receptor agonist + NMDA antagonist → reduces emotional dysregulation
4. Efficacy: Reduces episode frequency by ~50–75% in RCTs (PRISM I, PRISM II trials)
5. SSRIs (sertraline, fluoxetine): Often used first clinically; good evidence; low-cost
6. Amitriptyline: Older evidence; effective; anticholinergic burden a concern in stroke patients
7. Nortriptyline: Better tolerated TCA option

Non-pharmacological:

• Distraction during episode onset
• Controlled breathing
• Caregiver education and destigmatization

Answer 6: Chronic Traumatic Encephalopathy (CTE)

[6 marks]

Introduction

CTE is a progressive neurodegenerative disease resulting from repetitive traumatic brain injury (concussive and sub-concussive), characterized pathologically by accumulation of hyperphosphorylated tau in a perivascular distribution at the depths of cortical sulci.

Historical Context

• First described in boxers as "dementia pugilistica" or "punch-drunk syndrome" (Martland, 1928)
• Term CTE proposed by Corsellis (1973)
• Modern recognition in American football players, Dr. Bennet Omalu (2005)
• Affects military veterans (blast TBI), rugby players, ice hockey players

Neuropathology

• Hyperphosphorylated tau, p-tau accumulates in neurons, astrocytes, and cell processes
• Distribution: perivascular, at depths of cortical sulci, pathognomonic; distinguishes CTE from AD and other tauopathies
• TDP-43 inclusions in later stages
• Diffuse axonal injury background
• Cavum septum pellucidum (seen on MRI in boxers, "punched out" appearance)

Clinical Staging (McKee et al.)

Behavioral Profile

• Depression (60–80% in documented cases)
• Impulsivity and impulse control disorder
• Substance misuse (comorbid)
• Explosive aggression
• Paranoia
• Suicidality (elevated rates)
• Progressive cognitive decline (memory, attention, executive)

Diagnosis

• Currently a posthumous diagnosis, requires brain autopsy
• No validated in-vivo biomarker (research: tau-PET, plasma phospho-tau217, not yet clinical standard)
• Brain MRI: cavum septum pellucidum, cerebral atrophy (non-specific)
• Neuropathological criteria published by McKee et al. (2016)

Management

• No disease-modifying treatment
• Symptomatic: antidepressants, mood stabilizers for behavioral features
• Cognitive rehabilitation
• Prevention: primary goal, return-to-play protocols, rule changes in contact sports, helmet technology

Answer 7: Frontal Lobe Syndromes: Neuroanatomy and Clinical Features

[8 marks]

Introduction

The frontal lobe constitutes approximately 30% of the cerebral cortex and is the substrate for the highest human cognitive functions including executive ability, impulse control, working memory, and social behavior. Three distinct functional divisions produce clinically recognizable syndromes when damaged.

Three Frontal Syndromes

1. Dorsolateral Prefrontal Cortex (DLPFC) Syndrome, "Pseudodepression"

Anatomy: BA 9, 10, 45, 46; projects to caudate (dorsal striatum) via fronto-striato-thalamic circuit

Functions: Working memory, planning, cognitive flexibility (set-shifting), verbal fluency, abstract reasoning

Lesion features:

• Apathy, reduced motivation (resembles depression but no dysphoric mood)
• Poor planning and organization (Tower of London)
• Impaired set-shifting (Wisconsin Card Sorting Test)
• Reduced verbal fluency (FAS test)
• Executive dysfunction
• Working memory failure

Named "pseudodepression" because: Flat affect + apathy without subjective depression

2. Orbitofrontal Cortex (OFC) Syndrome, "Pseudopsychopathy"

Anatomy: BA 11, 12, 13, 14; projects to amygdala, nucleus accumbens, mediodorsal thalamus

Functions: Reward processing, decision-making with emotional context (Somatic Marker Hypothesis, Damasio), response inhibition, social cognition

Lesion features:

• Disinhibition, socially inappropriate behavior
• Impulsivity, failure of response inhibition (Go-No-Go test failure)
• Grandiosity, euphoria (can mimic mania)
• Hypersexuality
• Iowa Gambling Task failure (cannot use emotional signals to guide decisions)
• Reduced concern for consequences

Classic case: Phineas Gage (1848), frontal pole damage from iron rod → responsible, capable man becomes irresponsible, impulsive

3. Medial PFC / Anterior Cingulate Cortex (ACC) Syndrome

Anatomy: BA 24 (ACC); projects to SMA, limbic structures, thalamus

Functions: Motivated behavior initiation, error monitoring, conflict detection, attention allocation

Lesion features:

• Akinetic mutism (severe bilateral): awake, eyes open, track objects, yet mute and motionless, extreme amotivation
• Abulia (moderate): diminished spontaneous activity, slow speech
• Apathy (mild): passivity, reduced initiation
• Preserved cognition when explicitly prompted (vs DLPFC dysfunction)
• Classic cause: Bilateral ACA (anterior cerebral artery) infarct

Bedside Frontal Tests

Answer 8: Anosognosia: Definition, Neuroanatomy, and Clinical Significance

[5 marks]

Definition

Anosognosia (from Greek: a = without, nosos = disease, gnosis = knowledge) is a neurological condition in which a patient with a neurological deficit fails to recognize or acknowledge that deficit. First described by Joseph Babinski (1914).

Clinical Spectrum

• Anosognosia: Explicit denial of the deficit
• Anosodiaphoria: Acknowledges deficit but shows inappropriate indifference ("So what, it will pass")
• Hemispatial neglect: Inattention to contralesional space (related but distinct)
• Anton's syndrome: Denial of blindness in cortical visual loss (bilateral occipital)

Neuroanatomy

• Right parietal lobe, dominant for anosognosia of left hemiplegia
• Right supramarginal gyrus (inferior parietal lobule)
• Right somatosensory cortex integration areas
• Right temporoparietal junction
• Thalamus and right basal ganglia involvement in some cases
• Right frontal lobe, metacognitive awareness of deficits

Why right hemisphere?

• The right parietal lobe is dominant for body schema (awareness of the entire body including both sides)
• The left parietal lobe only represents the right side; the right represents bilateral space
• Right hemisphere lesions → impaired integrated body schema → anosognosia for left-sided deficits

Clinical Significance

1. Rehabilitation: Patient denies the deficit → refuses therapy → worsens outcome
2. Safety risk: Walking despite paralysis → falls, injury
3. Caregiver conflict: Family members frustrated by patient's apparent non-compliance
4. Prognostication: Persistent anosognosia predicts poor functional recovery

Management

• Direct confrontation (showing patient in mirror, video of deficits), variable success
• Prism adaptation therapy (for neglect component)
• Gradual insight may return as recovery progresses
• Involve caregiver in rehabilitation planning
• Goals-based rehabilitation rather than insight-dependent

Answer 9: Post-Concussion Syndrome: Diagnosis and Management

[6 marks]

Definition

Post-concussion syndrome (PCS) is a clinical syndrome following mild TBI (concussion) in which symptoms persist beyond the expected recovery period (>3 months after injury in ICD-10; >1–3 months clinically). DSM-5 classifies it as Mild Neurocognitive Disorder Due to Traumatic Brain Injury.

Symptom Triad

1. Somatic:

Headache (most common, tension-type pattern), dizziness, fatigue, sleep disturbance, photophobia, phonophobia, visual disturbance, nausea

2. Cognitive:

Memory problems, poor concentration, slowed information processing, word-finding difficulty

3. Affective/Behavioral:

Irritability, anxiety, depression, emotional lability, reduced frustration tolerance, personality change

Pathophysiology

• Neurometabolic cascade (Giza & Hovda): Ionic flux → glutamate excess → cellular energy crisis → mitochondrial dysfunction → period of neuronal vulnerability
• Disrupted cerebrovascular autoregulation
• Neuroinflammation
• Biopsychosocial model: Biological injury + psychological response (health anxiety, catastrophizing) + social factors (litigation, secondary gain, maladaptive return-to-activity patterns)

Risk Factors for Prolonged PCS

• Female sex
• Pre-existing headaches, anxiety, or depression
• Prior concussion
• Negative expectations at time of injury ("nocebo" effect)
• Younger athletes
• Delayed return to activity (over-resting paradox)

Management

Acute (first 24–48 hours):

• Cognitive and physical rest (brief; not prolonged)

Graduated Return to Activity (Stages, SCAT5 protocol):

1. Symptom-limited activity
2. Light aerobic exercise
3. Sport-specific exercise
4. Non-contact training
5. Full-contact practice
6. Return to competition

Symptom-specific:

• Headache: Amitriptyline (preventive), NSAIDs (acute), topiramate
• Sleep: Melatonin, trazodone, sleep hygiene
• Mood: SSRIs (sertraline), CBT
• Cognitive: Cognitive rehabilitation, graded return to school

Key principle: Avoid prolonged rest, causes symptom perpetuation (active recovery principle)

Answer 10: Transient Global Amnesia: Clinical Features and Differential Diagnosis

[5 marks]

Definition

Transient Global Amnesia (TGA) is a benign syndrome of sudden-onset, transient anterograde amnesia lasting up to 24 hours, in which the patient has intact personal identity and level of consciousness, with no other focal neurological deficits.

Clinical Features

• Age: Middle-aged to elderly (50–70 years)
• Abrupt onset: Often during or after a precipitant
• Dense anterograde amnesia: Cannot form new memories; no recall of the episode afterward
• Stereotyped repetitive questioning: "Where are we?" "What happened?", pathognomonic feature; same questions repeated every few minutes
• Preserved personal identity: Knows who they are, who family members are
• Normal consciousness and affect
• Retrograde amnesia: Covering hours before and during episode
• Complete resolution within 24 hours (by definition; average 4–6 hours)
• No focal neurological deficits

Common precipitants: Physical exertion, sexual intercourse, Valsalva maneuver, cold water immersion, emotional stress, migraine

Investigations

• MRI DWI: Small diffusion restriction spots in CA1 region of hippocampus, best seen 24–48 hours after onset (Sedlaczek sign)
• EEG: Normal, distinguishes from transient epileptic amnesia
• Vascular studies: Jugular venous insufficiency may be found (Valsalva mechanism)

Differential Diagnosis

Prognosis

• Recurrence rate: ~6% per year
• No increased stroke risk
• Completely benign condition, no treatment required
• Reassurance and education for patient and family

Answer 11: Vascular Cognitive Impairment: Classification and Management

[6 marks]

Definition

Vascular Cognitive Impairment (VCI) is an umbrella term encompassing the full range of cognitive impairment attributed to cerebrovascular disease, from vascular mild cognitive impairment (VaMCI) to vascular dementia (VaD).

Classification

Subtypes of VaD:

1. Multi-infarct dementia: Multiple large cortical infarcts; stepwise decline
2. Strategic infarct dementia: Single critical-site infarct (thalamus, angular gyrus, basal forebrain); abrupt, profound but focal deficits
3. Subcortical ischemic VaD / Binswanger's: Small vessel disease, leukoaraiosis, lacunes; executive dysfunction + gait + urinary symptoms; insidious
4. CADASIL: NOTCH3 mutation; hereditary subcortical VaD; migraine with aura + recurrent strokes + psychiatric features + dementia

Clinical Profile

• Onset: Abrupt or stepwise (vs gradual in AD)
• Executive dysfunction > memory (vs memory-first in AD)
• Gait disturbance (early in VaD)
• Focal neurological signs present
• Recall improved with cuing (unlike AD where encoding is impaired)
• Prominent mood features: depression, apathy, emotional lability

Management

• Vascular risk factor control: Hypertension, diabetes, hyperlipidemia, atrial fibrillation, primary treatment
• Antiplatelet therapy: Aspirin 100 mg or clopidogrel
• Statins
• Cholinesterase inhibitors (donepezil, rivastigmine): Modest benefit for VaD; RCT evidence
• Memantine: Some evidence; approved for moderate-severe AD; used off-label in VaD
• Manage neuropsychiatric symptoms (depression, apathy, agitation)

Answer 12: Autoimmune Encephalitis: Clinical Features, Diagnosis, and Psychiatric Relevance

[6 marks]

Overview

Autoimmune encephalitis (AE) is a group of conditions in which antibodies target synaptic or neuronal cell-surface antigens, causing encephalitis. Psychiatric presentation is common, often preceding neurological features, making it critical for psychiatrists to recognize.

Key Antibodies and Clinical Profiles

Investigations

• MRI brain: Bilateral temporal FLAIR/T2 hyperintensity (limbic encephalitis pattern)
• EEG: Delta brush pattern, pathognomonic for anti-NMDAR encephalitis
• CSF: Pleocytosis, elevated protein; anti-NMDAR antibodies (positive CSF more sensitive than serum)
• Serum antibodies: Combined serum + CSF increases sensitivity
• Screen for occult tumor (anti-NMDAR → ovarian teratoma; anti-LGI1 → thymoma)

Psychiatric Relevance

• Anti-NMDAR presents as acute psychosis in young patients → frequently misdiagnosed as first-episode schizophrenia
• Red flags suggesting AE over primary psychosis:
• Fever during psychiatric presentation
• Seizures
• Movement abnormalities (orofacial dyskinesias, catatonia)
• Rapid progression over days-weeks
• Autonomic instability
• Decreased consciousness
• Memory failure disproportionate to psychosis
• No response to antipsychotics (or paradoxical worsening)

Treatment

• First line: IV methylprednisolone 1g/day × 3–5 days + IVIG 2g/kg over 3–5 days ± plasma exchange
• Second line (refractory): Rituximab (anti-CD20) or cyclophosphamide
• Tumor removal if paraneoplastic: Accelerates recovery in anti-NMDAR (ovarian teratoma removal)
• With treatment: 75–80% achieve good recovery; risk of relapse ~12–25%

Answer 13: Delirium Superimposed on Dementia: Clinical Challenge and Management

[5 marks]

Introduction

Delirium superimposed on dementia (DSD) represents the most clinically complex scenario in hospital neuropsychiatry. Dementia is the single greatest risk factor for delirium (3–5× increased risk), and detecting delirium in a patient with existing cognitive impairment is diagnostically challenging.

Why DSD is Often Missed

• Hypoactive delirium (most common) mimics dementia progression
• No clear baseline cognitive state (especially in new patients)
• Fluctuation may be attributed to "sundowning"
• Staff assume confusion is the patient's baseline

Key Distinguishing Features

Detection Tools for DSD

• DOSS (Delirium Observation Screening Scale): 13-item nursing-administered tool; validated in dementia
• Nu-DESC (Nursing Delirium Screening Scale): 5 items; brief; practical
• SQiD (Single Question in Delirium): Ask family/caregiver: "Do you think your relative is more confused than usual?"

Long-term Consequences

• Accelerated cognitive decline (DSD → faster dementia progression)
• Increased mortality (3–11× in hospitalized elderly)
• Permanent institutionalization risk
• Loss of functional independence
• Persistent delirium in 30–40% at discharge

Management

1. Identify and treat precipitating cause (infection, dehydration, medication, constipation)
2. Minimize anticholinergic medications
3. Reorient frequently; familiar objects and faces
4. Maintain sleep-wake cycle
5. Low-dose quetiapine (12.5–25 mg) if behavioral disturbance severe
6. Avoid benzodiazepines
7. Family/caregiver involvement throughout

Answer 14: Neuropsychiatric Effects of Pituitary Tumors

[5 marks]

Introduction

Pituitary tumors (adenomas) produce neuropsychiatric effects via three mechanisms: mass effect on adjacent structures, hormonal excess from hyperfunctioning tumors, and hormonal deficiency from pituitary compression.

Neurological Effects (Mass Effect)

• Bitemporal hemianopia: Optic chiasm compression → loss of temporal visual fields bilaterally (tunnel vision)
• Headache: Dural stretching
• Cranial nerve palsies: Cavernous sinus invasion → III, IV, VI nerve palsies

Psychiatric Effects by Tumor Type

Cushing's Disease (ACTH-secreting):

• Depression, most common; often severe; melancholic features
• Anxiety
• Cognitive impairment (cortisol toxic to hippocampus → volume loss)
• Psychosis in ~5%
• Irritability, mood lability

Prolactinoma:

• Depression and anxiety (via hypogonadism, hyperprolactinemia → low testosterone/estrogen)
• Sexual dysfunction (libido loss, erectile dysfunction, amenorrhea)
• Treatment with dopamine agonists (cabergoline, bromocriptine), psychiatric symptoms often improve

Acromegaly (GH-secreting):

• Depression, anxiety, fatigue, quality-of-life impairment
• Sleep apnoea (common, worsens mood and cognitive function)

Non-functioning Adenoma:

• Subtle cognitive slowing from raised ICP and pituitary insufficiency
• Depression, fatigue from hypogonadism/hypothyroidism secondary to stalk compression

Principles of Management

• Cushing's: Surgery (transsphenoidal) first line; ketoconazole (cortisol synthesis inhibitor); mifepristone (glucocorticoid receptor antagonist) for psychosis
• Prolactinoma: Cabergoline first line; psychiatric symptoms track with prolactin normalization
• Psychiatric symptoms often improve with hormonal treatment but may persist, monitor
• Screen for depression and anxiety in all pituitary disease patients

Answer 15: Second Impact Syndrome: Mechanism and Prevention

[4 marks]

Definition

Second impact syndrome (SIS) is a catastrophic clinical event in which an individual sustains a second brain injury before fully recovering from an initial concussion, resulting in malignant, rapidly progressive cerebral edema.

Mechanism

• Neurometabolic vulnerability window: After the first concussion, the brain is in a state of ionic flux, mitochondrial dysfunction, and impaired cerebrovascular autoregulation
• A second impact, even minor, causes dysregulation of cerebrovascular tone
• Massive cerebrovascular vasodilation → rapid, bilateral cerebral swelling → herniation and death
• The second injury does not need to be severe, a minor head bump can suffice

Clinical Features

• Typically affects young athletes (teenage to early adult)
• Brief lucid interval after second impact
• Rapid neurological deterioration (collapse within minutes)
• Bilaterally dilated pupils; coma
• Extremely high mortality (~50%) and severe morbidity in survivors

Prevention (Primary Goal)

• Return-to-play (RTP) protocols: Athlete must be completely asymptomatic before returning to contact sport
• SCAT5 (Sport Concussion Assessment Tool): Standardized assessment; 6-stage RTP
• No same-day return to play after concussion, absolute rule
• Physician clearance mandatory before contact sport return
• Education of coaches, parents, athletes

Mnemonics & Memory Tricks

Mnemonic 1: DELIRIUM (Causes of Delirium) ★★★

Clinical anchor: The word itself = the condition. Anytime a patient is delirious, run through DELIRIUM top to bottom.

Recall hook: Delirium spells itself.

Mnemonic 2: CAM Criteria (Delirium Diagnosis) ★★★

Clinical anchor: Sensitivity 94–100%. In any exam question about delirium diagnosis bedside, CAM is the answer.

Recall hook: "AICA disrupts consciousness", just like delirium disrupts it.

Mnemonic 3: ROBINSON (Left Frontal Hypothesis for PSD) ★★★

Clinical anchor: Robinson → Left → Depression. Right → Mania.

Recall hook: "ROBinson → ROB the mood from the Left Front."

Mnemonic 4: GERSTMANN (Left Angular Gyrus Syndrome) ★★★

Clinical anchor: Left angular gyrus (BA 39). Dominant hemisphere. All four must be present for full syndrome.

Recall hook: "Gerstmann GAG-s on language": G=agraphia, A=acalculia, G=finger agnosia, ... plus L-R disorientation.

Mnemonic 5: WERNICKE'S TRIAD (Acute Thiamine Deficiency) ★★★

Clinical anchor: Full triad present in only ~16% of cases. Treat with thiamine if ANY one feature is present in an at-risk patient.

Recall hook: COA = "Caught Off Alert", Wernicke's catches you off guard with partial presentations.

Critical rule: Thiamine BEFORE glucose. "T before G, always."

Mnemonic 6: KORSAKOFF (Clinical Features) ★★★

Better device for differentiating confabulation:

Clinical anchor: Mammillary bodies + medial dorsal thalamus. Preserved procedural memory. Social skills relatively intact.

Recall hook: "Korsakoff MARC's memories, but they're all fabricated."

Mnemonic 7: NPH TRIAD (Normal Pressure Hydrocephalus) ★★★

Clinical anchor: Hakim's triad. Evans index >0.3 on CT. LP tap test (remove 30–50 mL CSF → gait improves). Treatment: VP shunt.

Recall hook: "Three W's = one confused, incontinent, shuffling patient."

Mnemonic 8: KLUVER-BUCY Syndrome ★★

Clinical anchor: Bilateral anterior temporal lobe destruction (amygdala + anterior temporal pole). Causes: Herpes simplex encephalitis, trauma, Pick's disease.

Recall hook: "Kluver-Bucy patients HHPVAP themselves, they can't stop putting things in their mouths."

Mnemonic 9: FOSTER KENNEDY SYNDROME ★★

Clinical anchor: Olfactory groove meningioma. Middle-aged woman. Psychiatric symptoms for years before diagnosis.

Recall hook: "FOSter Kennedy FOStered a brain tumor for years before anyone noticed."

Mnemonic 10: ANTI-NMDAR ENCEPHALITIS Red Flags ★★★

Clinical anchor: These are red flags that should trigger autoimmune encephalitis workup in a patient presenting as "first-episode psychosis."

Recall hook: "FARMS tell you it's NOT a farm-variety psychosis, it's autoimmune."

Mnemonic 11: CTE STAGES (McKee) ★★

Clinical anchor: CTE = posthumous diagnosis. Tau perivascular at sulcal depths. Repetitive TBI. Football, boxing, military.

Recall hook: "CTE beats you in the HEAD, four stages."

Mnemonic 12: TBI CLASSIFICATION (GCS) ★★★

Clinical anchor: Assess at 30 minutes post-injury (not immediately, confounded by hypoxia, hypotension).

Recall hook: "3-5-8: Mild is great (15), Severe is fate (3–8)."

Mnemonic 13: APHASIA TYPES ★★★

Recall hook: "Repetition intact = Trans or Anomic. Repetition impaired = everything else."

Mnemonic 14: FRONTAL LOBE SYNDROMES (Three Types) ★★★

Clinical anchor: Each maps to an anatomy and an eponymous syndrome.

Recall hook: "The front of your brain can either shut down (DLPFC), go wild (OFC), or go totally silent (Cingulate)."

Mnemonic 15: PSD TREATMENT (SSRIs for Post-Stroke Depression) ★★★

Clinical anchor: Sertraline = first choice for PSD. Fluoxetine = special status for motor recovery. Nortriptyline = older evidence, outperformed fluoxetine in some Robinson trials.

Recall hook: "FLAME lights up both motor and mood recovery, fluoxetine's double win."

Mnemonic 16: DELIRIUM SUBTYPES ★★★

Recall hook: "HYPOactive = HYPOthyroid, quiet, slow, deadly if missed."

Mnemonic 17: POST-STROKE PSYCHIATRIC SYNDROMES (DAMP) ★★

Recall hook: "Stroke leaves a DAMP MAP, navigate all of them."

Mnemonic 18: TGA DIAGNOSIS ★★

Recall hook: "TGA, 3 P's, 24 hours, benign. TEA, short, recurrent, EEG positive."

Mnemonic 19: AGGRESSION POST-TBI (Pharmacological) ★★

Recall hook: "Propranolol PRO-tects the TBI brain. Haloperidol HARMS it."

Mnemonic 20: AUTOIMMUNE ENCEPHALITIS ANTIBODIES ★★

Recall hook: "NLCAG, Navigate Limbic Circuits And Gaba, antibodies all attacking the synapse."

High-Yield Comparisons

Table 1: Delirium vs Dementia

Swipe to compare →

Table 2: Hyperactive vs Hypoactive Delirium

Table 3: Post-Stroke Depression vs Primary (Endogenous) Depression

Table 4: Mild vs Moderate vs Severe TBI

Table 5: Frontal Lobe Syndromes: Three Types Compared

Table 6: Organic Amnesia vs Dissociative Amnesia

Table 7: Vascular Dementia vs Alzheimer's Disease

Table 8: Post-Stroke Depression vs Post-Stroke Apathy

Table 9: Transient Global Amnesia (TGA) vs Transient Epileptic Amnesia (TEA)

Table 10: Pseudobulbar Affect (PBA) vs Primary Emotional Disorders

Bonus Table: Aphasia Types: Quick Comparison

PYQ Frequency Analysis

Section 1: Topic Frequency Heat Map

Swipe to compare →

Section 2: Question Pattern Classification

2.1 Long Answer Questions (10 marks each)

These questions require 4–5 pages of structured answer. The pattern consistently covers 3–4 sub-components.

Q1. "Discuss post-stroke depression. Include etiology, clinical features, and management."

Frequency: Asked in multiple exam sittings; virtually guaranteed across universities.

Expected sub-components:

• Definition + DSM-5 classification (1 mark)
• Prevalence data (1 mark)
• Robinson's left frontal hypothesis, detailed, with critique (3 marks)
• Risk factors, neurological + psychosocial (1 mark)
• Clinical features + assessment tools (2 marks)
• Management: pharmacological (sertraline, fluoxetine/FLAME, nortriptyline) + non-pharmacological (2 marks)

Key differentiator for high marks: Mention critiques of Robinson's hypothesis (community studies showed weaker lateralization; methodological heterogeneity). This shows analytical thinking rather than rote recall.

Examiner favourite additions: MADRS preferred over HDRS (less somatic item confounding); FLAME trial for fluoxetine; prophylactic sertraline evidence.

Q2. "Describe delirium, classification, pathophysiology, and management."

Frequency: One of the most reliably asked questions in Indian PG psychiatry.

Expected sub-components:

• Definition + DSM-5 criteria in full (2 marks)
• CAM criteria (1 mark)
• Classification by subtype: hyperactive / hypoactive / mixed with prevalence + prognosis (2 marks)
• Etiology (DELIRIUM mnemonic) (1 mark)
• Pathophysiology: cholinergic deficit + neuroinflammation + dopamine excess (2 marks)
• Management: HELP program (non-pharm) + pharmacological (haloperidol, quetiapine, dexmedetomidine) (2 marks)

Key differentiator: Naming hypoactive delirium as most common AND most missed AND worst prognosis consistently impresses examiners. Many candidates only describe hyperactive.

Q3. "Classify TBI. Discuss neuropsychiatric complications and their management."

Frequency: Regular across universities; especially strong in Exam pattern.

Expected sub-components:

• GCS classification table (mild/moderate/severe) + PTA duration (2 marks)
• Acute psychiatric effects (delirium, agitation) (1 mark)
• Post-concussion syndrome, symptoms, risk factors, management (2 marks)
• Personality change due to TBI, DSM-5 subtypes (1 mark)
• Depression, anxiety, psychosis post-TBI (1 mark)
• CTE, definition, neuropathology, stages (1 mark)
• Aggression management, propranolol, valproate, SSRIs; AVOID benzodiazepines and haloperidol (2 marks)

2.2 Short Answer Questions (5 marks each)

These appear in Section B or as "write short notes on." Average length: 1.5–2 pages.

Q4. "Korsakoff's syndrome."

Frequency: Very high; almost a fixture.

Expected content:

• Definition + etiology (thiamine deficiency, alcoholism)
• Neuropathology: mammillary bodies + medial dorsal thalamus (essential)
• Clinical features: anterograde amnesia, retrograde amnesia (Ribot's Law), confabulation (provoked + spontaneous), apathy
• Wernicke-Korsakoff continuum
• Treatment: thiamine IV before glucose; abstinence; external aids
• Prognosis

Key differentiator: Naming medial dorsal thalamus (not just mammillary bodies) as the critical lesion site for amnesia. Most candidates only mention mammillary bodies.

Q5. "Pseudobulbar affect (emotional incontinence)."

Frequency: High; asked as short note and as part of stroke complications.

Expected content:

• Definition: involuntary, uncontrollable laughing/crying incongruent with mood
• Mechanism: loss of corticobulbar inhibition of brainstem motor-emotional circuits
• Associated conditions (stroke, TBI, ALS, MS)
• Assessment: CNS-LS
• Treatment: dextromethorphan/quinidine (FDA-approved 2010; mechanism), SSRIs, amitriptyline

Key differentiator: Knowing the FDA-approved treatment by name (Nuedexta = dextromethorphan/quinidine) and its mechanism (CYP2D6 inhibition → elevated DM → sigma-1 receptor + NMDA modulation).

Q6. "Frontal lobe syndromes."

Frequency: High; asked as short note and within neuroanatomy questions.

Expected content:

• Three syndromes: DLPFC (pseudodepression), OFC (pseudopsychopathy), medial PFC/ACC (akinetic mutism)
• Anatomy of each
• Clinical features of each
• Classic cases: Phineas Gage (OFC)
• Bedside tests: FAB, Go-No-Go, Luria, FAS fluency

Q7. "Anosognosia."

Frequency: Moderate-high; reliable short note.

Expected content:

• Definition (Babinski, 1914): unawareness of neurological deficit
• Prevalence: 10–30%; right hemisphere strokes
• Neuroanatomy: right parietal (supramarginal gyrus, TPJ)
• Why right hemisphere: bilateral body schema representation
• Related syndromes: anosodiaphoria, Anton's syndrome, hemispatial neglect
• Clinical significance: rehabilitation refusal, safety risk, poor prognosis
• Management principles

Q8. "Transient Global Amnesia."

Frequency: Moderate; recurring short note favourite.

Expected content:

• Definition: sudden anterograde amnesia, <24 hours, preserved identity
• Age group (50–70 years)
• Pathognomonic feature: stereotyped repetitive questioning
• Precipitants: Valsalva, exertion, sexual intercourse
• Investigations: MRI DWI (CA1 dot, Sedlaczek sign), EEG normal
• Differential: TEA (shorter, recurrent, EEG abnormal)
• Management: reassurance; no specific treatment
• Prognosis: benign; 6%/year recurrence

Q9. "Post-concussion syndrome."

Frequency: Moderate; gaining frequency with sports psychiatry interest.

Expected content:

• Definition: symptoms >3 months after mild TBI (ICD-10: F07.2)
• Symptom triad: somatic, cognitive, affective
• Pathophysiology: neurometabolic cascade + biopsychosocial model
• Risk factors for prolonged recovery
• Management: active recovery (not prolonged rest), graded return, symptom-specific treatment
• Second impact syndrome: link and prevention

Q10. "CTE (Chronic Traumatic Encephalopathy)."

Frequency: Rising, increasingly tested in modern exams.

Expected content:

• Definition: progressive neurodegenerative disease due to repetitive TBI
• Historical context: boxers (dementia pugilistica), NFL players
• Neuropathology: hyperphosphorylated tau, perivascular at sulcal depths (pathognomonic)
• Posthumous diagnosis (no in-vivo validated test)
• Staging: McKee I–IV (HEAD mnemonic)
• Clinical profile: depression, impulsivity, aggression, memory loss
• Management: symptomatic; prevention emphasis

2.3 Very Short Answer / MCQ-Type Questions (2 marks)

These test isolated facts and definitions.

Section 3: Predicted High-Priority Questions for 2026

Based on trends in recent years and newly emerging clinical topics:

Almost Certain (>90% probability)

1. Post-stroke depression, Robinson hypothesis + management (Long answer)
2. Delirium, classification + CAM + management (Long answer)
3. Short note: Korsakoff's syndrome
4. Short note: Pseudobulbar affect

Very Likely (70–85%)

1. TBI psychiatric sequelae + management (Long answer)
2. Short note: Frontal lobe syndromes
3. Short note: Anosognosia or post-stroke mania
4. Short note: Post-concussion syndrome

Likely (50–65%)

1. CTE, rising trend in exams since 2022
2. Anti-NMDAR encephalitis, psychiatric presentation and diagnosis
3. Vascular dementia vs Alzheimer's (compare and contrast)
4. Transient Global Amnesia

Worth Preparing (Strategic)

1. Delirium superimposed on dementia, high clinical relevance, increasingly examined
2. Second impact syndrome, 4-mark short note; specific enough to differentiate candidates
3. Post-COVID neuropsychiatry, modern topic; asked in newer exams
4. Normal pressure hydrocephalus, classic triad + management

Section 4: Examiner Bias Analysis

Topics where candidates commonly lose marks

Section 5: Structured Answer Templates

Template A: For Stroke Psychiatry Questions

Template B: For Delirium Questions

Template C: For TBI Questions

Quick Review

Vignette 1: The Quiet Ward Patient

A 68-year-old retired school principal named Mohan was admitted to the neurology ward after a left hemisphere ischaemic stroke confirmed on MRI. He had a prior history of hypertension and hyperlipidemia, well-controlled. On day 5 post-admission, the ward nurse calls psychiatry because Mohan "hasn't been eating, barely responds to questions, and just stares at the ceiling."

On assessment: Mohan makes eye contact but offers minimal spontaneous speech. He shakes his head "no" to questions about pain or discomfort. His family reports that he was an active, engaged person before the stroke. He does not appear sad or tearful. BP and oxygen saturation are normal. No fever.

Questions

Q1. What is the most likely psychiatric diagnosis at this point?

Answer: Post-stroke apathy.

Mohan shows reduced motivation and goal-directed behavior without subjective distress, dysphoric mood, or tearfulness. He is not in pain, not febrile, and the presentation is specifically reduced output rather than subjective suffering. This profile, flat affect, reduced initiation, absence of distress, is the hallmark of apathy rather than depression.

Key distinction: Post-stroke depression requires dysphoric mood + subjective distress. Apathy = motivational syndrome without distress. Mohan does not appear to be suffering, he is indifferent.

Q2. What secondary diagnosis must be actively excluded, and how?

Answer: Hypoactive delirium.

Hypoactive delirium presents identically, withdrawn, reduced responsiveness, minimal spontaneous speech. Exclusion requires:

• CAM criteria: Check for acute onset relative to yesterday (fluctuation), impaired attention (digit span forward/backward), disorganized thinking
• Check for new metabolic disturbance (electrolytes, glucose, creatinine), urinary tract infection, medication review for anticholinergics or opioids
• If CAM positive with identifiable precipitant → delirium, not apathy

Teaching point: In a stroke patient who becomes suddenly less responsive, always delirium-first. Apathy is a diagnosis of exclusion once delirium is ruled out.

Q3. Mohan's workup is negative for delirium. What is the neuroanatomical basis of his presentation?

Answer: The anterior cingulate cortex (ACC) and frontal-subcortical circuits are the primary neuroanatomical substrates of apathy. His left hemisphere stroke may have disrupted the ACC, supplementary motor area, or their connections to the basal ganglia (caudate). These circuits are the substrate for motivated, goal-directed behavior.

Q4. What management would you recommend?

Answer:

• Behavioral activation: Structured daily schedule; nursing staff to prompt and engage rather than leave passive
• Caregiver coaching: Teach family to use open prompts and engage Mohan in familiar topics/activities
• Occupational therapy: Daily purposeful activity
• Pharmacological (if severe and persistent): Methylphenidate 5 mg BD (modest evidence) or rivastigmine, neither is first-line
• Treat any co-occurring depression that emerges
• Monitor for evolution into post-stroke depression

Vignette 2: The Weeping Engineer

Rajesh, 55, is referred to psychiatry from the neurology clinic 8 weeks after a right pontine stroke. He recovered well motor-wise and is back at his desk job part-time. His wife accompanies him and describes episodes where Rajesh "bursts into tears at the most random things", a news item, a mildly sentimental advertisement, his daughter calling from Pune. The crying lasts about 30–60 seconds and then he stops and resumes conversation normally. Rajesh is clearly embarrassed and states: "I don't even feel that sad most of the time. I don't know why I'm crying."

Questions

Q1. What is the diagnosis?

Answer: Pseudobulbar affect (PBA) / Emotional incontinence.

The hallmarks are present:

• Involuntary, uncontrollable episodes of crying
• Incongruent with subjective emotional state (he explicitly states he doesn't feel that sad)
• Brief and self-terminating (30–60 seconds)
• Occurs against a background of bilateral/pontine neurological disease
• No full depressive episode, he is functioning, working, not globally dysphoric

Q2. What is the neurological mechanism?

Answer: The right pontine stroke has disrupted descending corticobulbar pathways that normally exert tonic inhibitory control over the brainstem's motor-emotional expression centers. The loss of this inhibitory cortical brake allows minor emotional stimuli to trigger full involuntary emotional output that cannot be stopped voluntarily. Serotonergic and glutamatergic (NMDA) pathways are also implicated.

Q3. What tool would you use to assess severity?

Answer: The CNS-LS (Center for Neurologic Study, Lability Scale). It is a 7-item self-report scale assessing frequency of involuntary laughing and crying episodes.

Q4. Outline the treatment plan.

Answer:

• Psychoeducation first: Explain to Rajesh and his wife that this is a neurological symptom, not a sign of underlying severe depression or "losing his mind." Destigmatization reduces avoidance behavior.
• Dextromethorphan/quinidine (Nuedexta): FDA-approved 2010 for PBA. First-line when available. Quinidine inhibits CYP2D6, raising dextromethorphan levels. Mechanism: sigma-1 receptor agonism + NMDA antagonism reduces brainstem over-reactivity. Evidence: PRISM trials showed ~50–75% reduction in episode frequency.
• If Nuedexta unavailable: Sertraline 50–100 mg or fluoxetine 20 mg, SSRIs are widely used first in clinical practice due to cost and availability; good evidence.
• Behavioral: Distraction techniques during prodrome of an episode; controlled breathing.

Vignette 3: The Man Who Forgot Yesterday

A 72-year-old retired accountant named Venkat is brought to the emergency department by his wife. She reports that this morning, while they were having breakfast, Venkat suddenly became confused, kept asking "What are we doing today? Why am I dressed? Are we going somewhere?", the same questions, every few minutes, for about 4 hours. He did not fall, did not lose consciousness, and was fully aware of who he was and who his wife was. The episode resolved fully 5 hours after onset. Now in the ED, Venkat is completely back to baseline. Neurological examination is normal. Blood glucose: 95 mg/dL. ECG: normal sinus rhythm.

Questions

Q1. What is the most likely diagnosis?

Answer: Transient Global Amnesia (TGA).

The diagnostic features are all present:

• Sudden onset of transient anterograde amnesia
• Preserved personal identity throughout
• Repetitive stereotyped questioning, pathognomonic
• Full resolution within 24 hours (5 hours in this case)
• No focal neurological deficits
• Normal consciousness throughout

Q2. What investigation would confirm the episode on imaging, and when should it be performed?

Answer: MRI brain with Diffusion-Weighted Imaging (DWI). The characteristic finding is a small diffusion restriction dot in the CA1 region of the hippocampus, best seen 24–48 hours after the episode (Sedlaczek phenomenon). If done immediately, it may be negative. EEG should also be performed and is expected to be normal, this distinguishes TGA from transient epileptic amnesia (TEA).

Q3. His daughter, who is a doctor, insists this must be a TIA. How do you explain the distinction?

Answer:

Swipe to compare →

Key point: TGA does not increase stroke risk and requires no specific treatment. TIA demands urgent secondary prevention workup (carotid Doppler, echocardiogram, lipid panel, antiplatelet initiation). Venkat needs TIA workup to be safe, the clinical story does not fit TIA, but ruling it out is appropriate.

Q4. What is the prognosis and management?

Answer: TGA is a benign condition. Recurrence rate is approximately 6% per year. No treatment is required. Reassurance and education for the patient and family are the primary intervention. Advise Venkat to report future episodes immediately.

Vignette 4: The Disinhibited Executive

Priya, 47, is brought by her husband to the outpatient clinic. He describes a 2-year change in personality: previously a meticulous, reserved financial executive, she has become tactless, makes sexually inappropriate comments in social settings, spent ₹12 lakhs on an impulsive online shopping spree without telling him, and has been making jokes at her mother-in-law's funeral. She does not appear distressed about any of this behavior. Her MMSE is 27/30. MRI brain is reported as a "mass lesion in the right frontal region."

Questions

Q1. What syndrome best describes Priya's behavioral change?

Answer: Orbitofrontal Cortex (OFC) Syndrome, also called "Pseudopsychopathic Syndrome."

Features present:

• Disinhibition (socially inappropriate comments, impulsive purchases)
• Loss of response inhibition (cannot suppress inappropriate responses)
• Euphoria / indifference to consequences
• Hypersexual behavior (sexual comments)
• Lack of insight and concern (not distressed by her own behavior)

This is the classic OFC syndrome produced by damage to the orbitofrontal cortex (BA 11, 12, 13, 14).

Q2. The MRI shows a right frontal extra-axial mass with homogeneous enhancement and dural tail sign. What is the likely tumor, and what are additional psychiatric features to expect?

Answer: Meningioma, the dural tail sign (thickening of adjacent dura) and homogeneous enhancement are classic imaging features of meningioma. Right frontal convexity or parasagittal location.

If the mass involves the olfactory groove (anterior cranial fossa): expect anosmia (often unreported by patient) + Foster Kennedy syndrome (ipsilateral optic atrophy + contralateral papilledema).

Psychiatric features of frontal meningioma include: personality change (most common presentation), apathy or disinhibition depending on precise location, depression, cognitive slowing, and frontal release signs (grasp reflex, palmomental reflex). This presentation may mimic bipolar disorder (euphoria, impulsivity) or early dementia for years before diagnosis, which is why psychiatric presentations in middle-aged patients warrant neuroimaging before labeling as primary psychiatric disease.

Q3. How do you distinguish this from early-onset frontotemporal dementia (bvFTD)?

Answer:

Clinical rule: New-onset personality change or disinhibition in a previously reserved adult always requires MRI brain before any psychiatric label.

Vignette 5: The Boxer Who Forgot How to Box

Deepak, 38, is a retired state-level boxer who was forced to retire 3 years ago due to persistent headaches. He presents with his wife, who reports: progressive memory problems over 2 years, explosive anger with trivial frustration, two episodes of punching walls (no prior violence), 6 months of depression, and two episodes of cocaine use (new behavior, "he never touched drugs before"). MMSE: 22/30. MRI brain: cavum septum pellucidum, mild cerebral atrophy, no acute lesion.

Questions

Q1. What is the most likely diagnosis and what is required to confirm it definitively?

Answer: Chronic Traumatic Encephalopathy (CTE) is the most likely diagnosis given:

• History of repetitive head trauma (boxing career)
• Progressive behavioral syndrome: memory loss, explosive aggression, depression, new substance use
• Imaging: cavum septum pellucidum (characteristic in boxers, "punched out" appearance), cerebral atrophy
• Age: mid-thirties (consistent with CTE onset in high-exposure athletes)

Definitive diagnosis requires brain autopsy, CTE is currently a posthumous diagnosis. Neuropathological criteria (McKee et al., 2016) require demonstration of hyperphosphorylated tau in a perivascular distribution at the depths of cortical sulci. No currently validated in-vivo biomarker exists.

Q2. The wife asks: "Can anything be done?" What do you tell her?

Answer:

• No disease-modifying treatment currently exists
• Management is entirely symptomatic:
• Depression: SSRI (sertraline)
• Explosive aggression: Propranolol (best evidence for post-TBI aggression); consider valproate for affective aggression
• Cognitive decline: Cognitive rehabilitation strategies; external memory aids; structured environment
• Substance use: MI-based intervention; harm reduction
• Deepak should be assessed for suicide risk, CTE carries significantly elevated suicidality
• Family psychoeducation: understand the organic basis of the behavioral changes; reduce conflict and blame
• Safety planning: For aggression episodes, warning signs, de-escalation strategies for the family

Q3. What staging would Deepak likely fall into (McKee stages)?

Answer: Stage II–III.

• Stage II features present: Depression, explosivity, impulsivity, executive dysfunction
• Stage III features beginning: Memory loss (MMSE 22, suggesting moderate impairment), executive dysfunction
• Stage IV features absent: Severe dementia, Parkinsonism, speech/swallow difficulties, not yet present

Vignette 6: Delirium on the Orthopaedic Ward

Meena, 76, is a retired schoolteacher admitted for right hip replacement surgery. She has known mild cognitive impairment (baseline MMSE ~24), hypertension, and type 2 diabetes. On post-operative day 2, the nurses call psychiatry at 2 AM. Meena has been pulling at her IV line, shouting for people who are not there, and calling out her late husband's name repeatedly. She tried to get out of bed and was restrained. On assessment: Meena is disoriented to time and place, does not recognize her daughter, sees "children playing in the corner," and her attention is severely impaired.

Questions

Q1. Establish the diagnosis using formal criteria.

Answer: Delirium, DSM-5 criteria met:

• Criterion A: Disturbance in attention (cannot focus, sustain, or shift attention, does not recognize daughter, severely inattentive) AND awareness (disoriented to place and time)
• Criterion B: Acute onset (post-operative day 2, change from baseline), fluctuating course (was lucid on day 1)
• Criterion C: Additional cognitive disturbance, disorientation, visual hallucinations ("children in the corner"), misidentification
• Criterion D: Not attributable to another pre-existing NCD, the cognitive decline is acute and beyond her MCI baseline
• Criterion E: Direct physiological consequence of surgery (post-operative state, possible infection, pain medication, fasting, sleep deprivation, pain)

Subtype: Hyperactive delirium (agitation, pulling lines, shouting, visual hallucinations)

Q2. What predisposing and precipitating factors does Meena have?

Answer:

Predisposing (baseline vulnerability):

• Age (>70)
• Pre-existing mild cognitive impairment (2–5× risk)
• Female sex
• Prior functional impairment

Precipitating (acute triggers):

• Major surgery (hip replacement, high-risk orthopedic procedure)
• Post-operative state: pain, immobility, catheter (urinary retention risk), blood loss
• Opioid analgesics (prescribed post-op), anticholinergic + CNS depressant effects
• Sleep deprivation (hospital environment, pain, 2 AM intervention)
• Restraint application (restraints paradoxically worsen delirium by increasing agitation and distress)

Q3. What is your immediate management plan?

Answer:

Immediate (next 30 minutes):

1. Remove restraints, restraints worsen delirium; use 1:1 nursing sitter instead
2. Ensure Meena is safe (bed rails, call bell accessible, low bed height)
3. Reorient gently, name ("You are Meena"), place, time, familiar face (daughter at bedside)
4. Turn on a low light, complete darkness worsens hallucinations

Medical review (within 1 hour):

• Check vitals: temperature (infection), O2 saturation (hypoxia), glucose, BP
• Review medications: stop/reduce opioids if possible; substitute paracetamol + regional analgesia
• Urinalysis, FBC, CRP, U&E, creatinine, screen for UTI, electrolyte disturbance
• Check for constipation, urinary retention

Pharmacological (only if behavioral disturbance is dangerous):

• Quetiapine 12.5–25 mg: preferred in elderly with cognitive impairment; fewer EPS
• Haloperidol 0.5 mg IM: if immediate parenteral sedation needed; monitor QTc

Ongoing (next 48–72 hours):

• HELP program: orientation board, daytime lights, dayroom activity, sleep protocol at night
• Daughter to stay during day (familiar presence)
• Discontinue non-essential anticholinergic medications
• Hydration review

Q4. The family is upset and asks why this happened and whether Meena will "go back to normal."

Answer:

• Explain the biological basis: the stress of surgery temporarily disrupts brain chemistry, especially in older people with existing vulnerability (MCI). It is not a sign of a new stroke or permanent decline.
• Most delirious episodes resolve within days to weeks with treatment of the underlying cause
• However: In patients with pre-existing cognitive impairment, delirium can:
• Take longer to resolve
• Leave a residual cognitive "notch", some patients do not fully return to pre-delirium baseline
• Accelerate underlying MCI progression
• Long-term monitoring after this episode is warranted
• Reassure that this was recognized early and is being treated

Vignette 7: Post-Stroke Mania

A 61-year-old retired bank manager named Suresh presented to the casualty with what his wife described as a "complete personality flip" starting 3 weeks after a right hemisphere ischaemic stroke (MRI confirmed right basal temporal and thalamic infarct). He is sleeping only 2 hours a night, has made three large real estate investments without consulting his wife, speaks rapidly about plans to "start a foundation for stroke survivors," and has been making lewd jokes to the nursing staff. He has no prior psychiatric history.

Questions

Q1. What is the diagnosis?

Answer: Post-stroke mania (Secondary Mania Due to Stroke, DSM-5: Bipolar and Related Disorder Due to Another Medical Condition).

The features of a manic episode are present:

• Decreased need for sleep (2 hours)
• Grandiosity (foundation plans, large investments)
• Increased goal-directed activity
• Pressured/rapid speech
• Hypersexual behavior
• Impulsivity (real estate investments without judgment)
• Onset 3 weeks after right hemisphere stroke
• No prior psychiatric history (excludes primary bipolar disorder)

Q2. What neuroanatomical substrate explains this presentation?

Answer: The right hemisphere is the neuroanatomical substrate for post-stroke mania. Specifically:

• Right basal temporal region, documented in multiple cases of secondary mania
• Right orbitofrontal cortex
• Right caudate nucleus
• Right thalamus, also implicated

Proposed mechanism: Right hemisphere lesions release the left hemisphere from tonic inhibitory control, resulting in disinhibited, approach-oriented left hemisphere drives (positive affect regulation, approach behavior), manifesting as mania.

Robinson and Starkstein noted that secondary mania almost always follows right hemisphere lesions, in contrast to depression (left hemisphere predominance).

Q3. Outline the management.

Answer:

Pharmacological:

• Valproate: First choice in neurological setting, mood stabilizer; good safety profile in elderly; fewer drug interactions than lithium; can be given IV if needed
• Atypical antipsychotics: Quetiapine or olanzapine for acute behavioral control (decreased sleep, agitation)
• Lithium: Effective but narrow therapeutic index, requires renal monitoring; risk of toxicity in elderly; second choice
• Avoid: Carbamazepine (enzyme inducer, multiple drug interactions in stroke management)

Safety:

• Supervise financial decisions (PoA considerations if insight severely impaired)
• Prevent unsafe behavior (driving, large purchases)
• Caregiver safety and education

Monitoring:

• Episode often self-limiting (weeks to months) as brain reorganization occurs
• Follow-up for development of depressive phase (secondary bipolar cycle possible)

Vignette 8: The Young Woman Who "Went Crazy"

Kavitha, 22, a second-year engineering student, is brought to the emergency psychiatry unit by her parents. Over 3 weeks, she developed: mood changes and odd behavior (laughing inappropriately, socially inappropriate remarks) → escalating to auditory and visual hallucinations, persecutory delusions → seizure (generalized tonic-clonic, 2 days ago) → now reduced consciousness and appears posturing. Temperature 38.2°C. She has no prior psychiatric history.

Questions

Q1. What diagnosis must be urgently considered and investigated?

Answer: Anti-NMDA Receptor Encephalitis.

The clinical trajectory is the pathognomonic sequence:

1. Psychiatric onset (mood change, behavioral disturbance, psychosis), Stage 1
2. Seizures, Stage 2
3. Movement disorders / decreased consciousness, Stage 3
4. Autonomic instability, Stage 4 (may develop)

Red flags (FARMS) present: Fever, movement changes, Seizures, and rapid progression.

This is the most common autoimmune encephalitis. Young women are the most affected demographic. Ovarian teratoma must be urgently screened for.

Q2. What investigations must be ordered immediately?

Answer:

Urgent:

• MRI brain with FLAIR/T2 sequences (bilateral temporal signal change, limbic encephalitis pattern)
• EEG: Delta brush pattern, pathognomonic for anti-NMDAR encephalitis
• LP for CSF: cell count, protein, glucose, oligoclonal bands, anti-NMDAR antibodies in CSF (more sensitive than serum)
• Serum: anti-NMDAR antibodies, comprehensive metabolic panel, CBC, CRP
• Pelvic ultrasound / CT abdomen-pelvis: screen for ovarian teratoma

Supportive:

• LFT, renal function, electrolytes
• Blood cultures if fever persistent
• ECG

Q3. If confirmed, what is the treatment protocol?

Answer:

First-line immunotherapy:

• IV Methylprednisolone 1 g/day × 3–5 days
• IVIG 2 g/kg over 3–5 days
• Can use together or sequentially; combined approach often used

If teratoma found:

• Surgical removal (laparoscopic oophorectomy), accelerates neurological recovery; must be done even if small/asymptomatic

If no improvement in 10–14 days (Second line):

• Rituximab 375 mg/m2 weekly × 4 doses (anti-CD20 B-cell depletion)
• Cyclophosphamide (severe/refractory)

Symptomatic:

• Seizure control (levetiracetam, valproate)
• Antipsychotics for agitation (with caution; may need ICU)
• ICU management if autonomic instability develops

Prognosis: With early treatment, 75–80% achieve good functional recovery. Relapse in ~25%, requires long-term immunosuppression monitoring.

Q4. Her parents ask why she was treated for schizophrenia for 2 weeks before this diagnosis was made. What is the lesson?

Answer: Anti-NMDAR encephalitis is the great neuropsychiatric mimicker. Its initial psychiatric phase, behavioral change, psychosis, hallucinations, emotional lability, is clinically indistinguishable from first-episode psychosis or schizophrenia without additional workup.

The lesson for clinical practice: New-onset psychosis in a young person should trigger consideration of autoimmune encephalitis, especially when:

• Fever accompanies the psychiatric presentation
• Cognitive decline is rapid or disproportionate
• Seizures develop
• Movement abnormalities are noted (orofacial dyskinesias, catatonia)
• Antipsychotics show minimal or paradoxical effect
• No family history of psychotic illness

Routine MRI, EEG, and LP in new-onset psychosis (especially in young patients) would prevent delayed diagnoses.

Vignette 9: The Rugby Player with a "Mild" Head Injury

Arjun, 19, a state-level rugby player, sustained a concussion during a match, he was briefly confused, GCS 15 throughout, and was cleared within 30 minutes. He played the next match 4 days later (team pressure, "he seemed fine"). During the second match, he received a minor head contact with another player. Within 3 minutes, he collapsed on the field, became unresponsive, and was rushed to hospital with bilateral fixed dilated pupils.

Questions

Q1. What has occurred?

Answer: Second Impact Syndrome (SIS).

Arjun's first concussion placed his brain in a state of neurometabolic vulnerability, ongoing ionic flux, mitochondrial dysfunction, and critically, impaired cerebrovascular autoregulation. A second head impact during this vulnerable period, even trivially minor, triggered catastrophic loss of vascular autoregulation, resulting in:

• Massive cerebrovascular vasodilation
• Bilateral cerebral swelling (malignant edema)
• Rapid transtentorial herniation (bilateral fixed dilated pupils = herniation)

This sequence can unfold within minutes of the second impact, which is why it is almost always fatal or results in severe disability.

Q2. Who is primarily responsible for preventing this outcome?

Answer: Prevention is the responsibility of a multi-layered system:

• Team physician/medical officer: Must enforce return-to-play (RTP) protocols, no player returns before being fully asymptomatic
• Coach: Must not pressure players to return early
• Player: Must self-report symptoms accurately
• Parents/guardians (in minors): Must be educated
• Sports organization: Must enforce protocol with zero-tolerance rules

The SCAT5 (Sport Concussion Assessment Tool, 5th edition) mandates 6-stage graduated return to play, with each stage taking a minimum of 24 hours. Same-day return after any concussion is absolutely prohibited.

Q3. What are the management priorities in the emergency department?

Answer:

• ABC: Airway (intubate for GCS protection), Breathing, Circulation
• Neurosurgical emergency: CT head immediately, bilateral cerebral swelling (no focal hemorrhage typically)
• ICP monitoring
• Hyperosmolar therapy (mannitol or hypertonic saline) to reduce cerebral edema
• Head of bed elevation 30°
• Avoid hypotension and hypoxia (secondary injury)
• Neurosurgical consultation: decompressive craniectomy may be considered
• Prognosis: ~50% mortality even with aggressive management; severe disability in survivors

Vignette 10: Theft or Dementia?

Ramesh, 64, is brought by police to the hospital after being apprehended at a supermarket. He had walked out with items worth ₹800 in his pockets without paying. His wife, who came to the police station, insists "he has never stolen anything in his life." She also reports that for the past 18 months, Ramesh has been making "embarrassing comments" to strangers, bought a second-hand vehicle without telling her, and lost his previously meticulous attention to his accounts. His MMSE is 21/30. MRI: frontal and anterior temporal atrophy bilaterally.

Questions

Q1. What is the most likely diagnosis explaining this behavior?

Answer: Behavioural Variant Frontotemporal Dementia (bvFTD).

Ramesh's presentation includes:

• Disinhibition (shoplifting without guilt or insight, inappropriate comments)
• Impulsivity (vehicle purchase without consultation)
• Executive dysfunction (lost meticulous accounting skills)
• Social inappropriateness
• Progressive over 18 months
• Frontal and anterior temporal atrophy on MRI

BvFTD classically presents with behavioral change rather than memory loss. Patients frequently come to forensic attention before the diagnosis is made. Shoplifting, sexual offenses, and traffic violations are documented in bvFTD literature.

Q2. How would you counsel the police about proceeding with charges?

Answer: Ramesh lacks the mental capacity required for criminal intent (mens rea). The behavior is a direct consequence of his neurodegenerative condition, not volitional theft. A formal medicolegal report should include:

• Psychiatric diagnosis (bvFTD) with clinical and radiological evidence
• Assessment of insight and impulse control at the time of the incident
• Statement that he lacked capacity to form criminal intent
• Recommendation for charges to be dropped given medical basis
• Recommendation for supervision and care planning

This is a forensic psychiatry teaching point: frontal dementia and forensic presentations.

Q3. What management would you recommend for Ramesh?

Answer:

• No disease-modifying treatment exists for bvFTD
• Symptomatic: SSRIs (fluvoxamine, sertraline) reduce disinhibition and compulsive behaviors in bvFTD
• Caregiver education: the behavior is not intentional; it is neurological
• Financial and legal protective arrangements (PoA for finances; restrict independent access to money)
• Safety supervision: not to go to public places unaccompanied
• Driving assessment (likely unsafe, should cease driving)
• Genetic counseling: 30–50% of bvFTD cases have family history; MAPT, GRN, C9orf72 mutations
• Palliative planning for disease progression

Vignette 11: The Nurse Who Could Not Remember Her Patients

Sudha, 48, a senior ward nurse, is referred by her ward consultant. Over the past year, she has been making "silly mistakes", giving the wrong medications twice, forgetting discharge instructions she gave 2 hours earlier, needing her junior nurses to repeat information multiple times. She attributes it to "stress and overwork." MMSE: 27/30. MoCA: 23/30. Neuropsychological testing shows impaired verbal memory (delayed free recall) and mildly reduced executive function. MRI: mild white matter hyperintensities (Fazekas grade 1–2).

Past history: Hypertension (treated), diabetes (well-controlled), migraines with aura since age 30, two maternal uncles with "stroke-like events" in their 40s.

Questions

Q1. Given the family history and migraine with aura, what genetic condition must be excluded?

Answer: CADASIL, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.

Key features pointing toward CADASIL:

• Migraine with aura (characteristic early feature, often onset in 20s–30s)
• Young onset cognitive impairment with white matter changes
• Autosomal dominant family history (maternal uncles with early stroke-like events)
• No major vascular risk factors of sufficient severity to explain the WMH
• Pattern: subcortical cognitive impairment (executive + memory)

Confirm with: NOTCH3 gene mutation testing (blood) and/or skin biopsy (electron microscopy showing GOM, granular osmiophilic material deposits in small vessel walls).

Q2. What is the cognitive profile of subcortical vascular cognitive impairment?

Answer:

• Executive dysfunction predominant: Planning, set-shifting, divided attention, verbal fluency
• Memory: Encoding relatively preserved; retrieval impaired (unlike AD where encoding fails)
• Processing speed: Slowed
• Attention: Impaired
• Gait: May be abnormal even early
• Mood: Depression and apathy common

MoCA 23/30 with subtest analysis showing executive/attention deficits > memory encoding failure is consistent.

Q3. What are the immediate clinical management priorities?

Answer:

1. CADASIL workup: NOTCH3 mutation testing, skin biopsy, family screening
2. Vascular risk factor optimization: Strict BP control (<130/80), diabetes management, no smoking
3. Antiplatelet therapy: Aspirin 75–100 mg (prophylaxis against further lacunar events)
4. Occupational assessment: Her medication errors represent patient safety risk, referral to occupational medicine; may need supervised work reduction or role modification
5. Cognitive rehabilitation: Memory compensatory strategies, structured checklists, external aids
6. Mood screening: Depression is common; start SSRI if criteria met
7. Genetic counseling: For her children

Vignette 12: The ICU Patient No One Talks To

Sunil, 71, is on day 8 of a prolonged ICU admission for community-acquired pneumonia requiring ventilation. He was extubated 2 days ago. He is awake and can obey commands but has been "very quiet" since extubation. He does not speak spontaneously, responds minimally when addressed, and appears vacant. His family is concerned he "does not seem himself." Nursing staff feel he is "just tired." O2 saturation: 97%. Temperature: 37.1°C. Electrolytes: normal. No medication changes in 3 days.

Questions

Q1. What is the most important psychiatric diagnosis to consider and how would you assess it?

Answer: Hypoactive delirium, the most common subtype in ICU settings, and the most frequently missed.

Assessment using CAM-ICU (ICU-adapted Confusion Assessment Method):

1. Acute onset / fluctuation: Was there a clear change from his pre-illness baseline? Is behavior variable across shifts?
2. Inattention: Give RASS (Richmond Agitation-Sedation Scale) + attention testing, can he track 10 letters (SAVEAHAART), squeezing when "A" is spoken?
3. Disorganized thinking: Ask yes/no questions (Will a stone float on water? Are there fish in the sea?). Give a 2-step command.
4. Altered arousal: RASS score, any level other than 0 (alert/calm) is abnormal

If features 1+2+(3 or 4) are present → CAM-ICU positive = delirium

Q2. Why is this being missed?

Answer: Hypoactive delirium is systematically under-recognized because:

• It does not create behavioral problems for staff
• It is attributed to "being tired after illness" or "post-ventilation sedation wearing off"
• The patient does not demand attention
• Nursing and medical staff are trained to respond to agitation, not to absence of agitation
• "He's resting" is a common but dangerous assumption

The consequences of missed hypoactive delirium include: longer ICU stay, higher mortality, persistent cognitive impairment, longer ventilation duration, functional decline.

Q3. No new medical trigger is found. What does management focus on?

Answer:

• Stimulation and orientation: Speak to Sunil, name him, orient him, explain where he is and why
• Family presence: Have family speak to him (familiar voices are orienting)
• Sensory aids: Hearing aids if used; glasses
• Physiotherapy: Passive or active range of motion; sitting up if safe
• Sleep-wake normalization: Bright light during day; dark and quiet at night
• Remove non-essential medications: Review sedatives, H2-blockers, opioids, reduce/stop where safe
• Pharmacological: Not indicated for hypoactive delirium; quetiapine only if significant distress develops
• Monitor: Daily RASS and CAM-ICU; document trajectory